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Kenya, the Bio-Innovate Program is being implemented under four thematic areas and through 
nine regional, multi-disciplinary biosciences innovation and policy projects selected through 
the Program’s Competitive Grant Scheme (CGS). These activities focus on addressing key 
constraints in the agricultural and environmental subsectors in the region.
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I have the pleasure to introduce herewith the Manual on Standard Operating Procedures for the Bio-
resources Innovation Network for Eastern Africa Development (Bio-Innovate) Program supported 
innovation and policy projects. 
The Bio-Innovate Program is being implemented under four thematic areas and through nine 
regional, multidisciplinary innovation and policy projects selected through the Program’s 
Competitive Grant Scheme (CGS). 
To provide effective monitoring, review and evaluation of supported projects, a ‘Manual on Standard 
Operating Procedures for Bio-Innovate Program Supported Projects’ was prepared. It has been 
discussed at the Bio-Innovate Program Technical Advisory Committee (TAC) and was presented to 
the 2011 Sida-ILRI Annual Review Meeting where its publication was approved.
The Manual covers all the procedures involved in project implementation (decision-making 
processes, thematic calls, review processes, fund allocations, monitoring and evaluation, reporting, 
auditing, etc.). The TAC, the independent experts for technical project appraisal, the executing 
institutions, consultants, project evaluators, independent auditors, etc. should adhere to the 
procedures and guidelines prescribed in it to effectively operate a project from beginning to end.
The Manual is comprehensive, consolidating all the practices and experiences gained in the project 
development, approval and implementation of the Bio-Innovate Program, which have evolved as 
standard procedures. The Annexes of the Manual provide model guidelines and templates for certain 
key	procedures	and	results	of	specific	phases	of	the	consortium	project.
Seyoum Leta, PhD
Bio-Innovate Program Manager
International Livestock Research Institute, Nairobi, Kenya
Foreword
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The Manual on Standard Operating Procedures (SOPs) for the Bio-Innovate Program is a framework 
of practices and regulations for the Bio-Innovate supported projects’ implementation that should be 
followed from start to completion of a project. These procedures evolved as a result of the decision 
by the Bio-Innovate Program, the International Livestock Research Institute (ILRI) and the Swedish 
International Development Cooperation Agency (Sida), on the need for such a manual and the past 
experiences of various implementers of the Sida supported programs in the East Africa region. 
This manual has been prepared to guide the implementing institutions of the Bio-Innovate supported 
projects through the project cycle. The role and function of all actors, including the Bio-Innovate 
Program	Management	Office	(PMO),	the	Bio-Innovate	Technical	Advisory	Committee	(TAC),	Sida,	
the panel of experts, consultants and suppliers of goods and services, as well as independent auditors 
are detailed in order to optimize achievement of project objectives and expected results and impacts. 
The	specific	roles	and	responsibilities	of	all	parties	should	be	guided	by	applicable	procedures	
contained in this manual in all phases of the project.
Sections of the manual
Section 1
Provides a brief description of the Bio-Innovate Program, drawing from the Bio-Innovate program 
document, as approved by Sida in December 2009. 
Section 2 
Presents the Bio-Innovate Program management arrangements and the responsibilities of involved parties in 
the Bio-Innovate Program implementation. 
Section 3 
Describes the Bio-Innovate Competitive Grant Scheme and funding procedures for successful consortia of 
innovation and policy projects from the Bio-Innovate Program calls 1 and 2 for proposals. 
Section 4 
Outlines the Bio-Innovate project agreement processes and its signatories.
Introduction
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Section 5 
Shows the requirements for commencement of Bio-Innovate project implementation and disbursements of 
subsequent instalments of Bio-Innovate Funds.
Section 6
Provides the rules and procedures for Bio-Innovate project fund management, and financial reporting by 
implementing institutions. 
Section 7
Offers	guidance	to	implementing	institutions	and	to	the	Bio-Innovate	Program	Management	Office	
on required procedures to implement, monitor, review and evaluate Bio-Innovate supported innovation and 
policy	projects	from	the	first	and	second	calls	for	concept	notes.	It	provides	in	particular,	guidance	
for the executing institutions to set up and implement monitoring systems and to produce relevant 
consolidated technical and financial reports.
Section 8
Describes procedures for project suspension in the event of non-compliance to work plans, rules and 
procedures agreed between the parties.
Section 9
Provides criteria for project termination by the Bio-Innovate Technical Advisory Committee and the 
Bio-Innovate Program.
Section 10
Indicates the reporting requirements from Bio-Innovate Projects’ implementing institutions when the 
projects are completed.
Section 11
Outlines procedures and requirements for the completed projects accounts closure.
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1.1 Overview of the Program
The Bio-resources Innovations Network for Eastern Africa Development (Bio-Innovate) 
Program has been established to finance multidisciplinary biosciences and product-
oriented innovation activities in eastern Africa, more specifically in Burundi, Ethiopia, 
Kenya, Rwanda, Tanzania and Uganda. The focus is on the application of bio-resource 
innovations to support sustainable growth and transformation of the agricultural and 
environmental subsectors from primary production to value addition, while enhancing 
adaptability to climatic change and strengthening innovation policy. 
The Agreement to implement the Bio-Innovate Program was signed by ILRI and Sida 
on January 29, 2010 with a total grant of 80 million Swedish krona (SEK), equivalent to 
10.7 million United States dollar (USD), from Sida over the 5 years period (2010-2014). 
The Bio-Innovate Program also received an additional fund amounting to SEK 10 million 
(USD 1.3 million) for projects targeting climate change from the first call for proposals from 
Sida in September 2010 (Amendment Agreement 10 November 2011). This increased the 
overall Program budget fund to SEK 90 million (USD 12 million). This additional grant was 
used to support Bio-Innovate project consortia from the first call in thematic areas 1 and 2 
targeting climate change adaptation in agriculture and the environment in eastern Africa.
Building on previous investments, achievements and experiences from the Sida-supported 
East African Regional Program and Research Network for Biotechnology, Biosafety and 
Biotechnology Policy Development (BIO-EARN) Program (1999-2009) and other regional 
initiatives, the Bio-Innovate Program is focusing on delivering new products through 
biosciences innovation systems involving multiple actors, including scientists, private 
sector, non-governmental organizations (NGOs) and other development actors. The use 
of modern biosciences in practice to improve crop productivity and resilience to climate 
change in small-scale farming systems, and to increase the efficiency of the agro-processing 
Section 1
The Bio-Innovate Program
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industry to add value to local bio-resources in a sustainable manner is the major focus of 
the Program. The Bio-Innovate strategy is user-, market- and development-oriented in 
order to make a difference ‘on the ground’ supporting poverty alleviation and sustainable 
economic growth in eastern Africa.
1.2 Vision, mission and objectives  
Vision
The vision of the Bio-innovate Program is to develop into a program of excellence that 
contributes to sustainable and integrated utilization of bio-resources for economic growth 
and development of Eastern Africa, namely Burundi, Ethiopia, Kenya, Rwanda, Tanzania 
and Uganda. 
Mission
To create and promote bio-resource-based innovation systems in Burundi, Ethiopia, 
Kenya, Rwanda, Tanzania and Uganda for sustainable utilization and integration of the 
innovations into Eastern Africa’s economic development processes. 
Objectives
The key objectives of the Bio-Innovate Program are: 
a) To strengthen crop innovation systems to improve productivity and enhance food and 
nutrition security in the region. This objective aims at generating innovations to enhance 
crop adaptability to the consequences of climate change, to promote crop diversification 
and to reduce productivity constraints.
b) To develop and promote innovations on sustainable waste treatment and on securing 
freshwater resources, on producing bio-energy from renewable bio-resources and on mitigating 
climatic change. The target is to generate efficient and effective biosciences innovations 
for environmental clean-up, by-products utilization, waste management and sustainable 
use of resources (water and land).
c) To deliver innovative agricultural, environmental and industrial techniques that stimulate 
sustainable transformation, utilization and productivity of the region’s bio-resources. 
This objective targets the development and operationalization of technology incubation 
and other mechanisms for putting research into use by communities and industries. 
d) To develop and promote innovation policies for sustainable harnessing of bio-resources. The 
program will undertake policy support analysis studies to provide decision support 
tools for investment, promotion and management of bio-resource innovations in eastern 
Africa.
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e) To strengthen and operationalize an enabling mechanism for mobilization, catalysis and 
nurture of a strong bio-resource and science-led economic growth agenda for eastern Africa. This 
result will occur as an overall outcome of the above four actions being implemented 
successfully.
 
1.3  Bio-Innovate Program thematic areas  
The Bio-Innovate Program is being implemented under four Thematic Areas and through 
nine regional, multidisciplinary innovation and policy projects selected through the 
Program’s CGS. These innovation and policy project consortia are comprised of a range 
of value chain actors critical to span the process from science to production and markets. 
Involvement of market actors and other practitioners in the innovation project consortia is 
crucial in order to ensure that products, knowledge and new technologies emanating from 
the Bio-Innovate Program reach the market and specified end users. 
All of these are closely connected to and build on the AU/NEPAD Consolidated Plan 
of Action for Africa’s Science and Technology. In 2005, under the auspices of the AU 
and NEPAD, African countries designed and adopted Africa’s Science and Technology 
Consolidated Plan of Action (CPA). The CPA puts emphasis on improving the quality of 
African science, technology and innovation, especially through regional networking and 
more appropriate policies. Biotechnology and biosciences are prioritized areas in the CPA, 
which also have been explicitly manifested by a high-level AU/NEPAD African Panel on 
biotechnology. The panel describes its findings in the publication ‘Freedom to Innovate - 
Biotechnology in Africa’s Development’.
The four themes within the Bio-Innovate Program are also closely connected to each other 
and are all contributing towards a more productive and sustainable agricultural/agro-
processing sector in the region, as an engine for pro-poor economic growth. A more 
detailed description of the four thematic areas is provided below.
Thematic Area 1: Climate change adaptability, productivity and improvement 
for food and nutrition security
Generating and promoting technologies to boost productivity of strategically important 
crops under the threat posed by climatic change in the region is the main focus. Such 
crops are important to small-scale farming and rural livelihood strategies. The theme aims 
at unlocking genetic potential of the crops for climatic change adaptability and seeks to 
produce crop varieties that are high-yielding and resilient to biotic and environmental 
stresses while addressing nutritional quality. The focus is on important crops of the region, 
adding value to ongoing initiatives by tackling both input and output traits (processing 
BIO-INNOVATE   Manual  on Standard Operating Procedures
4
and other quality attributes). The innovations will boost food and nutrition security, lower 
food prices, offer more opportunities for income growth through crop diversification, and 
reduce crop intensification pressure in fragile agro-ecologies.
Thematic Area 2:  Waste treatment, production of bioenergy from renewable 
bio-resources and securing freshwater resources
This theme will focus on treatment of agro-processing waste through reuse, conservation 
of water and other bio-resources. It will also generate coping strategies, to reduce the 
impact of greenhouse gas emissions as well as generate innovations to enhance bioenergy 
recovery from solid waste and wastewater and for the provision of clean fresh water. 
Additionally, there will be emphasis on the use of agro-processing by-products, waste 
treatment and bioenergy production from existing and ongoing agro-processing activities 
in the region. The use of biowaste for making value added products such as improved 
feed, bio-processing reagents with selective catalysts, safe green chemicals, biofuels, biogas, 
bioplastics and biopolymers would serve the agro-processing sector in the region by 
making it more resource efficient and sustainable. Moreover, promoting the conversion of 
waste into renewable energy (such as biogas, biofuel, etc. through small-scale biorefineries 
at village level) will reduce the need to import costly fossil fuel and mitigate climate change 
through reduction of greenhouse gas emissions.  
Thematic Area 3:  Innovation incubation and promotion of targeted value 
chains 
Taking near-market products generated by the Bio-Innovate Program from the above 
two thematic areas and their partners along the value chain to end users. Research for 
development (R4D) institutions will apply for support to cover pilot-level testing for 
economic feasibility, marketability and acceptability. The program will seek opportunities 
for innovations that will have wide applications in eastern Africa as well as to leverage 
additional funds from other partners for venture capital and pilot testing activities.  
Thematic Area 4: Bio-resource innovation policy and sustainability analysis
Issues related to providing a supportive policy environment for the ultimate development, 
promotion and uptake of bio-resource innovations will be addressed. This will include 
policy analysis, national and regional policy support, as well as socio-economic and 
environmental analysis. The theme will address issues of sustainability analysis, in 
combination with Themes 1, 2 and 3 above, including:  
• Analysis of and addressing gaps in the technology dissemination chains within 
current and future projects. This would include analysis and exploration of roles and 
responsibilities along the value chain.  
• Market analysis and potential of addressing regional markets.
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• Exploring technology transfer models with a view to maximize the impact of new  
technologies, by achieving balance between making the technology as widely available 
as possible, while providing sufficient incentives to the innovators and investors for 
early adoption.
• Exploring and analysing models of funding of technology dissemination processes.
Other policy analyses on cost-effectiveness, socio-economic and environmental soundness 
as well as competitiveness will be made under this theme. A key question for the policy 
studies in the Bio-Innovate Program is to analyse how applications of biosciences in eastern 
Africa could lead to a more sustainable agricultural and agro-processing sector, able to 
promote economic growth and effectively alleviate poverty.
 
1.4 Program expected outputs 
The intended results of Bio-Innovate are: 
a) Strategic eastern Africa crop innovation systems will be strengthened to improve 
productivity and enhance food and nutrition security in the region. This result will 
generate innovations to enhance crop adaptability to the consequences of climatic 
change, to promote crop diversification and to reduce productivity constraints. 
b) Innovations for bio-remediation, for sustainable waste management and for mitigation 
of climatic change will be developed and promoted. Efficient and effective biosciences 
innovations for environmental clean-up and sustainable use of resources (water and 
land) will be generated.
c) Eastern Africa innovation systems will be catalyzed to deliver agricultural, 
environmental and industrial innovations that stimulate sustainable transformation, 
utilization and productivity of the region’s bio-resources. Technology incubation and 
other mechanisms for putting research into use by local communities and the local 
industry will be developed and operationalized. 
d) Innovation policies for sustainable harnessing of bio-resources will be developed and 
promoted. The program will undertake policy support analysis studies to provide 
decision support tools for investment, promotion and management of bio-resource 
innovations in eastern Africa.
An enabling mechanism for mobilization, catalysis and nurture of a strong bio-resource 
and science-led economic growth agenda for eastern Africa will be strengthened and 
operationalized. This result will occur as an overall outcome of the above four actions being 
implemented successfully.
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2.1 Governance and decision-making
2.1.1  International Livestock Research Institute (ILRI) - Bio-Innovate host 
institution
The agreement to implement the Bio-Innovate Program was signed by ILRI and Sida on 29 
January 2010. It stipulates that the Bio-Innovate Program is managed by ILRI with the day-
to-day management activities of the Program being undertaken by a small Bio-Innovate 
Program management team (PMT) hosted at ILRI. The primary responsibility of ILRI, 
as the signatory to the Bio-Innovate Agreement with Sida, is for the management of the 
Program and the funds, and for accountability to Sida for the use of the funds in accordance 
with the terms and conditions of the agreement between the parties (29 January 2010). This 
responsibility includes the set-up and management of the Bio-Innovate Program through a 
competitive grants scheme (CGS). 
In fulfilling the management responsibilities for the Bio-Innovate Program, ILRI provides 
the Bio-Innovate PMT at ILRI with the necessary professional and administrative 
support, human resources management and personnel services, legal advice from ILRI’s 
Contracts Office and other services required for the successful execution of the Program. 
Furthermore, ILRI shall ensure that administration and internal control of Bio-Innovate 
Program’s financial resources are adequately carried out by the PMT, through the use of 
ILRI’s financial and administrative systems.
2.1.2 Bio-Innovate Program management office
Day-to-day management will be provided by the program management office (PMO), led 
by the Bio-Innovate program manager and based at ILRI. The Bio-Innovate PMT comprises 
• a program manager and an assistant program manager 
• a finance and administration officer
• a program administrative assistant 
Section 2
Bio-Innovate Program 
management arrangements
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The PMT will be advised by an independent technical advisory committee (TAC) in 
implementation of its Program activities, through providing oversight on the Program, peer 
review of the competitive grant scheme, and Program monitoring and evaluation (M&E). 
Moreover, the PMT will be supported by independent technical review panels for scientific 
and technical review of the concept notes and full proposals. 
The PMO will be responsible for: 
• the set-up of the competitive grants scheme.
• the development of implementation guidelines to ensure efficient execution of Bio-
Innovate supported projects.
• the preparation of contracts for all institutions involved in the implementation of Bio-
Innovate supported projects. 
• serving as secretary to the Bio-Innovate TAC. 
• organization of the Bio-Innovate projects’ inception workshops, stakeholders meetings 
and project review meetings.
• coordination of marketing, advocacy and public relations to communicate Bio-Innovate 
activities and achievements.
• networking with relevant partners and stakeholders and ensuring that Bio-Innovate 
activities are harmonized and the necessary synergies are created both within and with 
other activities in the region.
• facilitating development of Intellectual Property Rights agreements between partner 
institutions.
• keeping up-to-date financial records and management standards in accordance with the 
financial and operational guidelines of the host institution (ILRI).
• designing financial reporting mechanisms in accordance with Sida reporting 
requirements and the institutional arrangements of the host institution.
• maintaining valid and accurate records pertaining to financial utilization by projects in 
the innovation program thematic areas.
• managing procurement and logistics and other administrative services for the Bio-
Innovate management team.
• preparing semi-annual and annual technical and financial reports for submission to Sida.
2.1.3   Scientific and technical management of the projects
The scientific and technical management is being taken care of by the TAC, independent 
experts and the thematic consortium leaders as described below.
The Bio-Innovate Program Technical Advisory Committee 
The role of the TAC is to provide technical expertise, to help with review and to give 
technical support to the whole Program. It will offer overall technical guidance to the Bio-
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Innovate PMO-ILRI and Sida. With the aim to enhance the integration of the Program into 
cross-cutting development issues, TAC members are drawn from core R4D institutions, 
universities and regional initiatives working in the Bio-Innovate Program thematic areas. 
The Bio-Innovate TAC consists of seven members: five independent experts not applying for, 
nor implementing Bio-Innovate projects, plus the African Union- the New Partnership for 
Africa’s Development (AU-NEPAD) African Biosciences Initiative (ABI) director as a voting 
member of TAC and the BecA-ILRI hub director as a non-voting member.  A rotating chair 
will be elected from among the TAC members. The TAC shall meet at least semi-annually 
in person and by teleconference in the alternating quarters, if so requested by the TAC chair 
and/or the Program manager. The Bio-Innovate Program manager serves as secretary to the 
Bio-Innovate Technical Advisory Committee. The Bio-Innovate PMO in consultation with 
Sida is responsible for putting the TAC in place and TAC members are appointed for two 
years, renewable. 
The roles and responsibilities of the TAC are:
• to ensure consistency of the Bio-Innovate program with regional agendas particularly 
with the AU-NEPAD Consolidated Plan of Action for Africa’s Science and Technology and 
other regional and continental initiatives.
• to evaluate and advise on the relevance and importance of the Program achievements 
and the impact on development in the region.
• to develop, in collaboration with the PMO, the detailed terms of reference of the various 
thematic calls for proposals and corresponding monitoring and evaluation criteria 
thereof.
• to provide peer review mechanism for the competitive grants scheme.
• to make recommendations to the PMO on fund allocations for competitive grants.
• to provide technical guidance on program implementation issues including a regular 
review and assessment of program/project outputs/outcomes to ensure that the 
Program maintains a high international standard.
The panel of independent experts
Furthermore, a panel of independent experts has been set up to support in the scientific 
and technical review of concept notes and full proposals before the TAC will start final 
deliberations on them. Panel members are internationally recognized individuals from the 
fields of agricultural and environmental biosciences and development. All independent 
experts possess a high level of professional experience in the public or private sector in 
research and/or practice in biosciences innovation systems with extensive experience in 
eastern Africa and have also experience in one or more of the following areas: 
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• evaluation of projects
• use of the results of research and technological development projects to solve 
development challenges in agriculture and the environment
• up-and-out scaling of innovations
• policy and value chain analysis 
Both the technical reviewer panels and the TAC have advised the PMO on the first and second 
calls for concept notes and full proposals. The TAC also made recommendations to the PMO on the 
Bio-Innovate grants to be awarded from the competitive grants fund, in order to create a balanced 
portfolio of projects, taking into account the objectives of the call, the quality of the proposals, the 
advice from the evaluators and the availability of funding. The Bio-Innovate PMO and ILRI in 
consultation with Sida will finally approve the fund for  recommended projects.
Thematic consortia project leaders
Within the eastern Africa region, thematic project consortia leaders (PLs) are responsible for 
respective thematic area project consortia, hosted at lead institutions in the Bio-Innovate participating 
countries. The innovation consortia and their thematic project consortia leaders were selected via the 
competitive grants scheme, for implementation at institutions within the region as shown in Figure 1 
below. 
The thematic leaders will be responsible for: 
• routine management of the projects within their consortium.
• ensuring that the individual projects within each consortium contribute to the overall objectives of 
the Program and deliver the intended results/outcomes. 
• support to project teams in management of operations.
• ensuring that effective communications and the necessary scientific synergies are maintained 
within the consortium and with other program thematic area projects.
• coordination of contractual arrangements between the PMO and the project teams. 
• preparation of all consortium projects work plans, and progress and financial reports and their 
submission to the PMO.
• maintaining valid and accurate records pertaining to innovation consortium projects. 
• preparation of summary briefings on the Program consortium projects for use during monitoring 
and evaluation. 
• working closely with the PMT on dissemination activities.
• addressing problems within the program consortium projects including operation of projects. 
• facilitating signing of memorandums of understanding and material transfer arrangements. 
among innovation project implementing institutions.
• performing any other activities for the smooth operation of the consortium projects.
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 Technical Review Panel
Lead implementing institution
for consortium Project 1 
Lead implementing institution
for consortium Project 2
Lead implementing institution
for consortium Project 3 
Lead implementing institution
for consortium Project 4 
Lead implementing institution
for consortium Project 5 
Lead implementing institution
for consortium Project 6 
Lead implementing institution
for consortium Project 7 
Lead implementing institution
for consortium Project 8 
Lead implementing institution
for consortium Project 9 
SIDA – ILRI Management
Bio-Innovate Program
Management Office - ILRI
Bio-Innovate Program
Technical Advisory Committee 
Figure 1: Bio-Innovate Program management structure.
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3.1 Bio-Innovate competitive grants scheme 
The Bio-Innovate Program is implemented through four thematic areas in the sectors 
on climatic adaptation strategies in crop agriculture, as well as agro-waste treatment, 
technology incubation and in policy advice and advocacy. Each consortium will consist of 
a number of individual but related projects. These consortia  selected via a Bio-Innovate 
competitive grants scheme (CGS). 
The CGS will be operated through a number of strategically developed calls for proposals 
in the four thematic priority areas described in Section 1.3. The priorities are closely linked 
to the needs and strategies for the region and in support of the AU-NEPAD agenda for 
science and technology. 
The steps and processes involved in the competitive grant scheme from the point of call for 
concept notes through to final funding are schematically indicated in Figure 2 below.
Section 3
Granting mechanisms and 
decision-making on fund 
allocations
BIO-INNOVATE   Manual  on Standard Operating Procedures
12
1. Call for Concept
Notes on thematic focus
areas of Bio-Innovate
Program
6. Approval of
Concept Notes
by Bio-Innovate
Technical Advisory
Committee (TAC)
7. Development of
Concept Notes into
full Proposals, 
facilitated by the 
Bio-Innovate PMO
12. Funds released
for successful
projects
13. Implementation,
monitoring and evaluation
of projects
14. Completion and
evaluation of projects
11. Subcontract
signing arrangement
by Bio-Innovate PMO
10. Full proposals
endorsed by
Bio-Innovate TAC
8. Submission of full 
proposals by
applicants to
Bio-Innovate PMO
9. Full proposals
subjected to review
and comments
by peer reviewers
2. Submission of
Concept Notes by
applicants to
Bio-Innovate PMO
5. Comments
submitted to
Bio-Innovate PMO
4. Eligible Concept
Notes further
reviewed externally
by peer reviewers
3. Preliminary
screening of
Concept Notes
at Bio-Innovate
Secretariat
Figure 2: The main processes and procedures followed in a competitive grants scheme 
starting from the thematic focus areas of the Bio-Innovate Program.
BIO-INNOVATE   Manual  on Standard Operating Procedures
13
3.1.1  Calls for concept notes 
At the start, the PMO in consultation with the TAC develops guidelines for calls for 
concept notes addressing the thematic areas described earlier and sends out a call for 
concept notes/proposals. In the initial phase the concept notes are reviewed on their merit 
and prospective success and on this basis a first selection is made. Teams of successful 
concept notes are then requested to develop these into full proposals for further review 
and for the final decision on eligibility of funds granting. The emphasis is on regional, 
multidisciplinary innovation consortia, each consisting of a small number of distinct but 
interlinked innovation and policy projects over a three-year period in the four thematic 
areas. 
3.1.2 Composition of consortium teams
Project consortium teams are drawn from within and outside of the region. The 
participating countries in eastern Africa are Burundi, Ethiopia, Kenya, Tanzania, Rwanda 
and Uganda. Collaborating institutions from the public and private sectors from within and 
outside of the region are involved at various levels of support in the innovation process. 
Each call is designed to ensure regionality, relevance, efficiency and impact orientation. 
The innovation projects are also designed to ensure up- and out-scale results to the region 
as well as to create the required enabling policy environment for effective uptake and 
application of bio-resources innovation in eastern Africa.
3.1.3 Co-funding
Strong institutional support from consortium actors is a prerequisite/deciding factor in 
the decisions to approve granting of Bio-Innovate Program funds. This may be based on 
either provision of matching funds and/or in kind contributions of staff, infrastructure and 
other institutional support. The Program will be able to explore and form new and strategic 
partnerships, and develop joint interdisciplinary research and policy oriented projects with 
like-minded partners in an effective manner. 
3.1.4 Decisions for funding 
The selected Bio-Innovate consortia and their component projects will have a clear and 
highly strategic value to the region, based on national and regional strategies, and add 
value to already ongoing national and regional initiatives, avoiding duplication of efforts. 
Therefore, funding is only given to innovation and policy projects where it can be clearly 
demonstrated that a regional approach is more effective than individual national projects. 
It is also dependent on the demonstrated ability and capacities of partners to achieve 
the objectives and after successfully passing a rigorous peer review process as shown in 
Figure 2 above. Evaluation of proposals is carried out by the TAC, following a peer review 
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process by at least three independent experts. The TAC then makes recommendations 
on the successful awards to the Program management team for endorsement of the final 
project portfolio to be funded through the Competitive Grants Scheme. Bio-Innovate-
ILRI and Sida in agreed minutes decide on the projects for funding based on the 
recommendations from the TAC. Lead institutions of successful innovation and policy 
projects then sign a sub-agreement with ILRI for funding by the Bio-Innovate Program.
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4.1 Processing of the project sub-agreement
The Bio-Innovate Program supported project sub-agreement is prepared by the Bio-
Innovate Program secretariat immediately after a consortium innovation and policy project 
has been recommended by the Bio-Innovate Technical Advisory Committee and approved 
by the Bio-Innovate PMO-ILRI and Sida for funding. Such an agreement specifies the roles 
and responsibilities of the lead executing institutions and collaborating partner institutions, 
and the Bio-Innovate PMO in implementing the projects based on the project document as 
described in this Manual on Standard Operating Procedures.
The executing institution reviews the sub-agreement and if acceptable signs and forwards 
it to the Bio-Innovate PMO-ILRI. The project sub-agreement becomes effective with 
signatures by all the parties concerned. A template for a project agreement specifying the 
contractual obligations and other pertinent provisions is shown in Annex 1.
The project agreement among other provisions includes detailed procedures with regard 
to:
• execution of the project
• use of Bio-Innovate project funds
• accounts, records, and reports
• publication and technical reports
• procurement and assets management
• project suspension
• project termination
• settlement of disputes
• modification of the agreement
Section 4
Project contractual 
arrangements
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4.2 Signatories to the project sub-agreement
The accepted signatories to the project sub-agreement are the duly appointed 
representatives of the International Livestock Research Institute and of the Bio-Innovate 
project executing institutions for the project. Specifically, these signatories are the Director 
General of ILRI and the heads of the executing institutions. The project agreement enters 
into force upon signature by all the contracting parties.
 
4.3 Complementary agreement(s)
All collaborating partner institutions identified in the project document shall execute a 
consortium agreement (CA) with the executing institution to establish the relationships 
amongst them in project implementation. Such an agreement shall define the role of each 
institution, the amount and schedule of their counterpart contributions, and reporting and 
monitoring requirements. It also defines and governs any movement of genetic materials 
between and among collaborating partner institutions. This has also to be submitted to the 
Bio-Innovate PMO as a requirement for the release of the first payment for implementation. 
A model consortium agreement and material transfer agreement (MTA) between an 
executing institution and collaborating partners is shown in Annex 2 and 3, respectively.
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5.1 Commencement of the implementation of a project
A project formally commences, after the signing of the project sub-agreement. The project 
commencement is supported by the first instalment of funds for starting up the initial 
activities of the project based on the approved yearly plan of activities as shown in 
Section 5.2. 
The Bio-Innovate secretariat will record the actual commencement of every project for 
management and monitoring/evaluation purposes and other activities related to the 
implementation until the completion phase of the project cycle.
5.2 Inception planning meeting arrangements and inception report
An inception planning meeting involving all project teams has to be conducted within two 
months after receiving the first instalment by executing institutions. 
The inception planning meeting report provides the necessary information that preparatory 
activities are in place for project implementation. The consortium project leader must 
confirm in the report that: 
• Adequate preparations in terms of the necessary project inputs such as facilities, project 
sites and related arrangements are in place. 
• A separate account has been opened for the project.
• Core project personnel have been teamed up.
• An agreement contract or MOU if any has been entered into with any collaborating 
agencies.
• A Yearly Plan of Activities for the first year (YPA 1) has been prepared.
Section 5
Project implementation
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The YPA1 will most likely not differ much from the activities or work plan, and budget in 
the project document other than the starting date and some minor adjustments. The YPA1 
has to be attached to the inception report. 
Further, the principal investigator (PI) shall notify formally the Bio-Innovate PMO in 
writing that the project is ready to commence with the completion of preparatory activities 
for implementation as contained in the inception report.
The format for the inception report with the complete table of content is given in Annex 4
5.3  Requirements for disbursement of subsequent instalments of 
Bio-Innovate project funds 
The disbursement of subsequent instalments of Bio-Innovate project funds to support the 
project’s activities as per approved yearly plan of activities (YPA) will be made by the Bio-
Innovate PMO upon receipt of biannual progress reports (see Section 6)  and cash flow 
statements showing the balance of funds from the executing institutions and a justified 
request for payment in terms of the timing, amount, and costs foreseen in the YPA  taking 
into account the stage of implementation for the period relating to the use of requested 
funds.
The final disbursement will be made by the Bio-Innovate PMO upon submission of the last 
biannual progress report and a justified request for payment considering the costs foreseen 
in the last YPA submitted to successfully complete the project.
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6.1  Financial management
Financial management is an integral part of project management. Therefore it must not 
be seen as a separate activity to be left to finance staff only. Financial management entails 
planning, organizing, controlling and monitoring the financial resources of the project to 
achieve objectives. At the heart of financial management there is financial control.
6.2  Financial control
Can be described as a situation where the financial resources of a project are being correctly 
and effectively used. Hence, financial control occurs when systems and procedures are
established to make sure that the financial resources of a project are being properly handled.
6.3  Practical requirements for disbursement of the first instalment of 
Bio-Innovate funds
Submission of an officially signed sub-agreement, opening a separate bank account for the 
Bio-Innovate project funds accompanied by an official fund transfer request letter are pre-
requisite for the first disbursement.
Funds for collaborating institutions shall be sent directly to their specified institutional bank 
accounts. Each cooperating institution shall open and maintain a separate bank account 
for Bio-Innovate project funds received for the project. 
ILRI will remit the funds to the institutional bank account specified for each of the 
collaborating institutions. However, requisitions shall be routed through the principal 
investigator (PI) for approval and subsequent submission to the PMO-ILRI. 
Section 6 
Bio-Innovate Program 
fund management
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The following will accompany the initial request for funds:
• a fully signed copy of the partner sub-agreement
• proof of a separate account opened and maintained for the Bio-Innovate project
• yearly activity and budget plans for each consortium partner
Any interest the funds may yield has to be separately accounted for in the financial 
reporting and utilized within the project after approval by the PMO-ILRI in conformity 
with Sida requirements. Interest not utilized within the Program shall be repaid to Sida 
through ILRI.
6.4  Practical requirements for disbursement  of subsequent 
instalments of Bio-Innovate funds
Requests for further disbursements shall be accompanied by a report on the utilization 
of funds previously disbursed. No disbursements shall be made unless a financial 
report covering the previous period indicating the use of at least 75% of the previous 
disbursement and a request for disbursement of funds for the following period have 
been received by the PMO-ILRI.
The disbursements shall be made as follows:
a) The Bio-Innovate PMO-ILRI shall transfer the first 50 % instalment from the first year 
budget to be deposited, upon signature of the sub-agreement.
b) The second 50% instalment from the first year budget, will be transferred after receipt by 
the Bio-Innovate PMO of the first consolidated biannual project progress report and the 
financial report from the consortium project leader in accordance with the procedures 
of the Bio-Innovate Program, and a justified request for the payment in terms of the 
approved project budget commensurate with the YPA, in light of implementation thus 
far, for the period to which the funds shall relate.
c) The third instalment corresponding to 50% from the second year project budget, 
will be transferred after an identical procedure as detailed above but adjusted to the 
corresponding period of operation (i.e. production of second biannual report).
d) The fourth instalment corresponding to 50% from the second year project budget, 
will be transferred after an identical procedure as detailed above but adjusted to the 
corresponding period of operation (i.e. production of third biannual report).
e) The fifth instalment corresponding to 50% from the third year project budget, will 
again be transferred after an identical procedure as detailed above but adjusted to the 
correspondingperiod of operation (i.e. production of fourth biannual report).
f) the sixth and final instalment corresponding to 50% from the third year project budget, 
will be transferred after an identical procedure as detailed above but adjusted to the 
corresponding period of operation (i.e. production of fifth  biannual report).
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The following will accompany the subsequent project fund requests from the specific 
institutions:
• a financial report for the preceding six month period with accompanying support 
documentation
• a progress report for the preceding six month period
• an activity plan and budget for the next  six month period
• approval from the respective consortium principal investigator
6.5  Withholding fund disbursement 
The PMO-ILRI may decide to withhold the disbursement, wholly or in part in the following 
circumstances:
• if substantial deviations from the project plan and budget occur 
• if the main objective(s) is/are endangered
• if reports are not delivered as agreed
• if the project progresses unfavourably in terms of the objective(s) in any other important 
respect
The PMO-ILRI shall however, initiate discussions with the concerned project partners 
before taking such a decision. In case of substantial deviation from project plans and 
budgets presented in the partner sub-agreement, the PMO-ILRI may reclaim the disbursed 
amount, wholly or in part from the concerned project partner(s).
 
6.6  Records management
6.6.1 Importance of record keeping
The creation and maintenance of records is integral to the operation of the management 
system, and there is an implicit assumption that records of all actions are correctly kept and 
filed and are available to support each stage of the management cycle.
6.6.2  Maintaining financial records
A record is created for each financial transaction. Some are created by the project (e.g. 
orders for payment or for goods); others are created by entities with which the project deals 
(e.g. suppliers’ invoices, bank statements). ALL records pertaining to a specific financial 
transaction must form part of that transaction.  Records must be preserved and classified 
for easy access because they provide the paper trail on which the accounting system is 
based. 
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A good record-keeping system facilitates financial accounting and reporting, internal 
control, project management and subsequent auditing. Records represent a particularly 
valuable type of information because they can provide verification and are therefore 
suitable as legal evidence. When project financial management systems are being 
designed and/or reviewed, the maintenance of records, and their computerization are 
also considered. Finance and audit laws generally require entities to ensure that financial 
and accounting records are adequately kept. This helps those involved with the project (in 
particular the auditor) by providing supporting documentation for transactions. 
As an example, supporting documentation to a payment would be:
• a payment voucher 
• a supplier’s/provider’s invoice 
• a delivery note / receipt
• a quotation
• a local purchase order (LPO)
• a purchase requisition
• a confirmation of payment from the paying institution 
• acknowledgement receipt of payment from the receiving institution
The financial records, including their creation, filing, storage, must be maintained in such a 
manner that it will facilitate ease of reference and production of reports.
NB: It is important to ensure the following in the above documents:
• legible narration of what the transaction relates to
• relevant dates
• relevant requesting, approving, authorizing signatures
• clearly stated amount
• relevant stampings for example “PAID”…etc.
6.6.3  Scope of records management system
For developing a sound records management system, project staff should ensure that:
• there are clearly defined procedures for creating, maintaining and safeguarding 
records.
• the records management procedures address the location and maintenance of 
records relating to project participating agencies, particularly for projects which have 
decentralized project implementation.
• records, including computerized records, are properly secured from fire, water, other 
environmental risks, and from unauthorized access.
BIO-INNOVATE   Manual  on Standard Operating Procedures
23
• there are adequate back-up procedures, particularly with respect to computerized 
records.
• there is easy access by authorized persons including auditors.
6.7  Internal controls
6.7.1 Introduction
Internal control is a process carried out by an institution’s management, designed to 
provide reasonable assurance that the objectives of the institution are being achieved in the 
following categories:
• effectiveness and efficiency of operations
• reliability of financial and operational reporting
• compliance with applicable laws and regulations
Internal control consists of specific policies and procedures which are often called 
’controls‘. These controls fall into the following five categories:
• control environment
• risk assessment
• control activity
• information and communication 
• monitoring
The control environment is the foundation for the other four main components of 
internal control (from risk assessment to monitoring in the above list). Where the control 
environment is weak, the other components of internal control are not likely to be effective. 
The purpose of internal control is to identify strengths and weaknesses and to judge 
whether: 
• an executing institution’s existing policies and procedures can be used and relied upon 
for the project’s financial management functions
• supplementary systems and procedures are required for the project
• shortfalls in existing systems need to be addressed
6.7.2  Expected internal controls in the Bio-Innovate project
The following are some of the most essential expected internal controls:
• holding a separate bank account for the Bio-Innovate project
• having a minimum of two signatories to a bank account
• separating of duties and responsibilities: for example a financial transaction could 
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undergo a series of at least three stages i.e. the initiator, the preparer and the authorizer
• existence of sound internal control procedures and policies
• adherence/compliance to internal procedures
• safe custody of assets, etc.
6.7.3  Participating institutions’ responsibilities
The management in the respective institutions should ensure that there exist established 
procedures to identify, analyze and manage the risks that may arise from internal and 
external sources that may affect the project. These procedures would cover defining, 
identifying, analyzing and managing risk. The implementing institution’s management 
should develop policies and procedures to ensure that its directives are followed. 
This would require:
• appropriate documentation of the policies and procedures, covering management of 
finances, accounting, procurement and financial reporting
• suitable authorization procedures, e.g. for the award of contracts by authorized 
personnel
• appropriate segregation of duties and responsibilities (for instance certain 
responsibilities such as authorization, custody, record keeping and accounting duties 
should be segregated)
• adequate measures for safeguarding project assets, including cash and bank balances
• arrangements for carrying out accounting reconciliation and independent verification of 
assets and records
• arrangements for storing project documents and restricting access to unauthorized 
personnel
6.7.4  The accounting system
The accounting system gathers processes and organizes accounting data in order to 
produce useful financial information. It should reflect project needs and be designed 
to provide the financial information required by all interested parties and fulfil all the 
legal and regulatory requirements of the borrower country. The accounting system is a 
critical part of the project’s financial management system and its design and operation are 
therefore of great importance. 
It should:
• provide information compatible with the agreed accounting standards
• be simple and user-friendly
• be capable of installation and maintenance by implementing institution’s staff, and be 
easily understandable by users
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• provide adequate documentation and audit trails
• provide reliable and timely information, including financial management and other 
reports
• maintain integrity
The right accounting system
Since organizations are different, it would be difficult to find a single finance system that 
would suit all organizations. Therefore, a number of deliverables could be expected to 
consider an accounting system as a right one for the organization:
• having several authorization levels to ensure system security and authenticity in entry 
and management of financial data
• having the ability to generate summary and detailed financial reports
• showing flexibility to accommodate various accounting transactions for example cash 
and credit purchases, prepayments…etc.
• possessing the ability to accommodate multiple projects while keeping track of 
individual project transactions
• holding flexibility to meet various donors reporting requirements - for example having 
the ability to generate timely reports to meet financial reporting schedules, and to 
generate reports in donor reporting format or at least ease with transforming system 
generated reports into specific donor report formats, internal management reports etc. 
• being easy to use and economical to acquire and maintain
The above considerations will guide on decisions about the most appropriate:
• method for maintaining accounting records - for example who will be responsible for 
data entry, verification, posting, adjustments
• coding structure for transactions - so that project transactions can be tracked accurately 
and produce a variety of user reports for donors and the project management team
• financial policies - whether to accommodate only cash or accrual transactions or both
• financial reporting routines - the frequencies at which reports are prepared as per donr 
requirements or for timely information in management/project team decision-making 
processes
Chart of accounts
Probably the most important tool for organizing financial transactions is a chart of 
accounts. Financial activities/transactions make sense when they are sorted into a series 
of predetermined categories (accounts). These accounts when listed and typically arranged 
in a logical order, are referred to as the Chart of Accounts. Therefore, when day-to-day 
transactions take place, they are recorded in the books of accounts and categorized by the 
guidance held in the chart of accounts. These categories are used in the organization’s 
budgets and reports, hence promoting consistency and transparency.
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Each executing organization’s chart of accounts would include an account name, account 
number and a description for use of the account. 
6.8 Procurement
Procurement processes should be efficient and sound while ensuring transparency, fairness 
and integrity in contract management and in line with Sida procurement guidelines {for 
details refer to Sida Procurement Guidelines (SPG)-June 2004}.
6.9  Financial reporting
The consortium projects financial information on fund utilization should be frequently 
reviewed to ensure that it can generate reports that will satisfy the Bio-Innovate 
reporting requirements and facilitate managing project operations. This includes suitable 
arrangements for communicating financial information to the project leader, project teams 
and Bio-Innovate PMO; arrangements for maintaining effective communication with the 
executing institutions and project leaders and the Bio-Innovate PMO; clear procedures 
for preparing, signing and submitting the financial report required by the Bio-Innovate 
Program.
The format for the Bio-Innovate biannual project financial report is given in Annex 5.
The arrangements for periodic comparison of actual project activities against plan, and 
regular evaluation of systems should be reviewed. They should enable the PMO and 
project teams to assess the quality and performance of the internal control system. 
These arrangements would include:
• inventory taking and verification, and report preparation and distribution
• internal and external audits
• clear procedures for timely reporting of important deficiencies and audit findings to the 
PMO, and for taking appropriate actions
6.9.1 Financial reporting arrangements for the Bio-Innovate projects. 
Financial reporting will be carried out biannually based on the budget and activity plans 
for the reporting period and comply with all applicable accounting standards.
The following will constitute a  biannual or annual financial report:
• a summary financial report as per the official standard reporting template duly signed.
• a ledger supporting the figures in the periodical financial reports.
• supporting documents relating to all figures reported.
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• an updated inventory list for assets procured under the Bio-Innovate fund.
• a copy of the project cash book and bank statement reconciled.
• any other relevant documentation as may be requested from time to time.
• half-year progress and financial reports shall be sent to the PMO - ILRI by latest 
July 30th of every project year.
• annual project reports must be submitted to the PMO - ILRI, latest by January 31st each 
program year. Annual reports must follow the general format provided by the PMO-
ILRI.
• in case of substantial deviation from project plans and budgets presented in the partner 
sub-agreement, the PMO - ILRI may reclaim the disbursed amount, wholly or in part 
from the concerned project partner(s).
6.10  Auditing
In line with Sida’s new audit requirement, audits will be conducted for all recipients of 
Sida funding on a yearly basis. The objectives and scope of the audit shall be guided by 
the ISA 315 as a basis for risk assessment and issue a report thereof in accordance with 
the ISA 800. According to the International Federation of Accountants (IFAC) ISA 315, 
Identifying and Assessing the Risks of Material Misstatement Through Understanding the Entity 
and Its Environment, deals with the auditor’s responsibility to identify and assess the risks 
of material misstatement in the financial statements through an understanding of the 
entity and its environment, including the entity’s internal controls and risk assessment 
process. ISA 800, Special Considerations-Audits of Financial Statements Prepared in Accordance 
with Special Purpose Frameworks, deals with a special purpose framework which is a 
financial reporting framework designed to meet the financial information needs of specific 
users. The financial reporting framework may be a fair representation framework or 
compliance. Adequate and complete documentation shall be maintained for the purposes 
of the audits. 
Some specific audits will entail: 
• Examining, assessing and reporting on compliance with the terms and conditions of the 
agreement and applicable laws and regulations.  
• Examining if there is supporting documentation related to reported expenditure. The 
auditor shall report the identified amount in case there is any missing supporting 
documentation.
• Submission of an audit memorandum/management letter, which shall contain the audit 
findings made during the audit process. The audit memorandum/management letter 
shall state which measures have been taken as a result of previous audits and whether 
measures taken have been adequate to deal with reported shortcomings.
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6.10.1 Selection of external financial auditors and submission of audit annual 
final financial reports
The Project Agreement specifies that the Bio-Innovate supported projects implementing 
institutions should submit to the Bio-Innovate Program biannual and annual progress 
reports and financial statements.
The audit of all expenditures incurred by Bio-Innovate project implementing institutions 
for the purposes of executing the project is carried out centrally at the Bio-Innovate 
PMO-ILRI annually. To expedite the auditing process, Bio-Innovate project implementing 
institutions shall submit all ORIGINAL vouchers together with the financial statements 
to the Bio-Innovate PMO-ILRI on a biannual basis. The cost for the audit shall be borne 
by ILRI from the Bio-Innovate Program budget. The Parties shall co-operate with and 
assist the auditor for the auditing mission. Original vouchers and the related support 
documentation should be made available for the audits.
The project accounts shall be audited by duly recognized independent auditors selected by 
ILRI in consultation with Sida. The auditor shall be selected by obtaining and evaluating 
quotations from at least three audit firms. 
The Bio-Innovate Program shall be audited annually by an external, independent and 
qualified auditor, in accordance with international standards. The selection and terms 
of reference of the auditor shall be prepared by the PMT, in consultation with ILRI and 
approved by Sida.
The external auditor is expected to conduct a full scope audit in accordance with generally 
accepted auditing standards. The auditor will submit an audit report which shall include 
the auditor’s opinion, general information and financial statements. A financial audit 
management report prepared by the auditor will also be required if there are significant 
internal control weaknesses and irregular transactions and activities. ILRI should sign a 
letter of representation prepared by the auditor stating to the best of their knowledge and 
belief that the financial statements contain all transactions and that the statement of account 
is complete and accurate in all respects.
6.10.2 Auditing requirements
The project financial statements of all Bio-Innovate supported projects are audited 
annually. 
6.10.3 Scope of audit
Audits of financial statements for the funded projects include:
• an assessment of the adequacy of accounting and internal control systems to monitor 
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expenditures and other financial transactions and ensure safe custody of project-
financed assets
• establishment whether the project implementing entities have maintained adequate 
documentation of all relevant transactions
• verification that the expenditures submitted to the PMO-ILRI, are eligible for Sida 
financing, and identification of any ineligible expenditures
• verification that the annual financial statements can be reconciled with the relevant year 
to date amounts appearing in the reports submitted to the PMO-ILRI
6.10.4 Audit checklist
Check that 
• reporting is in accordance with agreed conditions 
• activities for which funds were awarded have been carried out
• the factual report and financial report do not contradict one another
• costs incurred according to fund accounts agree with accounts of the project/program 
kept in the Bio-Innovate PMO-ILRI
• costs stated in accounts agree with actual supporting documentation and/or examined 
reports from recipient party (project, institution ...)
• the self-funding component has been accounted for correctly
• the organization has signed an agreement with local partner organizations to which it 
channels grant funds
• the lead organization has received a report with an audit certificate as agreed from each 
local partner organization, and that it has examined this audit
• the lead organization has a separate bank account for Bio-Innovate funds and that 
transactions with it are  signed by a minimum of two individuals in the executing 
organization
• received and accrued interest on Bio-Innovate funds is accounted for correctly
• it is stated in the final report if funds are to be paid back
6.10.5 Monitoring audit compliance
The ILRI-PMO ensures that consultations take place among the project team handling the 
Bio-Innovate project at the implementing institutions and ILRI-PMO in order to identify 
necessary remedial actions. For example:
• inadequate financial management: provide technical assistance to the implementing entity
• unacceptable quality of financial statement: request submission of acceptable financial 
statements
• ineligible expenditures: require additional evidence of eligibility of the expenditures, 
submission of documentation for other eligible expenditures, or a refund of the amount 
disbursed
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7.1 Introduction
Bio-Innovate strives to ensure that funding is being used as efficiently as possible and with 
a maximum impact. Therefore, it is necessary for all actors and parties to implement a 
continuous and rigorous monitoring and evaluation (M&E) component. This section sets out 
required procedures to implement,  monitor, review and evaluate Bio-Innovate supported 
projects. It provides particularly guidance to the executing institutions to set up and apply 
monitoring systems and to produce relevant and consolidated technical and financial reports.
The M&E system for Bio-Innovate shall allow the Program to evaluate its working 
performance in terms of strategy and direction, research and program development, 
effectiveness, approach and management, outputs created, internal communication and 
collaboration, fundraising efforts, uptake of outcomes and impacts in society. 
Each project is required to use the LFM to produce clear log frames on outputs, outcomes 
and activity schedules, which will be closely monitored by the PMT. Annual peer review 
evaluations will assist the TAC making an assessment whether projects are on track. 
Consortia, projects and/or project components that seem not effective or not achieving 
desired outputs will be reviewed by the PMT, on the advice of the TAC and will be 
informed and guided to make adjustments.  If this still does not lead to satisfactory 
adjustments for progress towards achieving the mutually agreed annual milestones and 
results, the PMO-ILRI may decide for early termination of the project. Unused funds from 
any such terminated projects shall be reallocated by the PMT, after consultation with Sida. 
In order to manage efficient M&E and potential reallocations of Program budget, effective 
reporting regimes and routines have also been developed by the PMT and included in this 
manual as well as in the sub-agreement.
Section 7
Project monitoring and evaluation
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7.2 Project monitoring, review and reporting
7.2.1 Monitoring
Monitoring is the continuous process of collecting and analyzing data (indicators), with 
a view to identify any need for corrective actions to ensure correct project execution 
towards attaining its objective.
The basis for a quality result-based project management system is the ‘Plan, Implement, 
Follow-up, and Evaluate approach’, where follow-up is the monitoring part of the 
approach.
Monitoring verifies the actual situation in relation to the planned situation. It starts, 
once the project proposal has been approved and funded. Depending on the outcome of 
monitoring, actions may be required to adapt implementation. Monitoring is a procedure 
of continual search for efficiency and effectiveness.
At the Bio-Innovate project, implementing institutions need to monitor four factors:
1. Resource use efficiency (input): the timely availability of inputs, e.g. project staff, 
funds, equipment, and timely and proper execution of activities and working processes, 
used as indicators in the yearly activity plans and budget.
2. Output: delivery and quality of outputs (direct results) using indicators as presented in 
the logical framework in the approved consortium project document. The Logframe will 
be used within the project, especially at the activity level to ensure delivery on output 
level in terms of focus, budgetary compliance, progress and overall compliance. 
3. Outcome: is the extent to which the specific objective has been achieved, using 
indicators as presented in the logical framework matrix in the consortium project 
document, e.g. response of target beneficiaries to (use) project outputs.
4. Impact: is a fundamental and sustainable change in conditions after project 
implementation. Impact is linked to the development objective. Therefore the social, 
economic and environmental impacts should be described in terms relevant to the 
development objective, using indicators as presented in the logical framework matrix 
in the consortium project document and defined in impact assessment reports as far as 
they are available.
A basic monitoring system consists of:
• identified objects and indicators to be examined pertaining to input, including 
expenditures, output, outcome and impact (what?)
• methods/means of verification and frequency of data collecting concerning the 
indicators (how, when, by whom?)
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• processing and analysing of the data
• defining corrective actions
Internal monitoring by the executing institution and the consortium project 
leaders
All partners involved in the implementation of the Bio-Innovate projects, i.e. lead 
implementing institutions and collaborating partners have a built-in internal monitoring 
system in the approved consortium project in order to ensure successful execution of the 
consortium project. Implementing this monitoring system must be part of the planned 
activities in the yearly plans of activities. The internal monitoring system is a results-based 
management tool that should be effectively utilized to improve project performance.
The internal monitoring system of all partners should ensure successful implementation of 
the project including adjustments of the yearly plan of activities (YPA) and implementation 
according to defined corrective actions.
The selection of ‘what should be monitored’ and ‘by what indicators’, is crucial for the 
effectiveness of a monitoring system. The LFM and the yearly work plans provide the basis 
for the monitoring activities. 
Internal monitoring should include the following subjects:
• follow-up commitments resulting from the agreement between the Bio-Innovate the 
PMO-ILRI and the executing institutions.
• progress and proper execution of planned consortium project activities, as per the 
indicators outlined and yearly activity plans provided in the project document. The 
consortium project leader, and where appropriate the collaborating institution, must:
• monitor the actual performance of the project team as well as the availability of funds
• verify that task leaders for activities of a specific project component have the 
appropriate technical and personal qualifications
• anticipate and monitor delays in disbursements of funds
• anticipate and monitor conditions, such as adverse weather, which may slow down 
or delay activities
• ensure timely preparation and submission of progress and financial reports by 
project task leaders
• on-time delivery and quality of the outputs, using indicators as presented in the LFM in 
the project document.
• the extent to which the Specific Objective has been achieved, using indicators as 
presented in the logical framework matrix in the project document, e.g. response of 
target beneficiaries to (use) project outputs.
• social, economic and environmental impact and the effect of mitigating measures, using 
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indicators referring to the Development Objective, as presented in the LFM in the project 
document and defined in impact assessment reports as far as they are available.
Results of internal monitoring by the consortium project leaders (PIs) will show if and 
where there is need for corrective actions and for enhancing performance of the consortium 
project teams. These results are incorporated in progress reports submitted to the Bio-
Innovate Program. The structure and format of these reports should be compatible with the 
monitoring system.
The format for the Bio-Innovate biannual project progress report is given in Annex 6.
They also provide useful data and guidelines to any PMO conducted external monitoring. 
Internal monitoring by the Consortium Project Leader and Bio-Innovate Secretariat should 
be conducted annually preferably immediately prior to the schedule of TAC meetings. 
It consists of review of pertinent progress and other reports of a project, interviews with 
project management and stakeholders, and field visits to validate accomplishments. Prior 
planning must be done to identify the documents to be reviewed, who to interview for 
results and problems, and to look at specific areas where reported accomplishments can be 
validated on the ground.
Monitoring these matters enables mitigating measures and prevents confrontation with 
unexpected delays in delivering the outputs. It may be useful for setting up an early 
warning system to anticipate possible delayed inputs or no shows. The system would check 
availability of planned inputs well ahead as well as shortly before their planned use.
Implementation of the monitoring system must be part of the planned activities in the 
work plan. Findings of internal monitoring are not only a basis for action but also enable 
the project task leader to report objectively and promptly to the higher consortium Project 
Leader. This is necessary if there is any need to adopt preventative or corrective actions, or 
simply to keep them informed on the project progress and situation. Outcomes of internal 
monitoring should be fed into progress reports. The structure of the progress reports and 
the internal monitoring system should be attuned to each other. Progress reports should 
present relevant data in the Bio-Innovate project progress reporting format.
External monitoring
The external monitoring of a consortium project is undertaken by the Bio-Innovate PMT 
and the TAC, supported by external experts where necessary. Therefore the information 
provided in the progress reports must come in a format adequate to be analyzed and 
registered by the Bio-Innovate Program.
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The Bio-Innovate Program relies on the information from the PI’s consolidated technical 
and financial reports, to monitor project implementation and to react when necessary. 
This must enable the Bio-Innovate PMO to:
• assess whether these projects are proceeding according to the agreed work schedules, 
so that the necessary Bio-Innovate PMO actions (e.g. disbursements to the executing 
institutions) may be taken
• propose and participate in any necessary reviews of the projects as a result of these 
assessments
• report to the TAC and Sida on the situation and on the completion prospects of the 
project
7.2.2 Review
Part of monitoring procedures is the project review. 
Project review is a specific formal examination of project implementation towards 
attaining its objectives, as part of the project monitoring activities
The periodic project review is part of the Bio-Innovate Program’s own monitoring 
function and constitutes an important element in the process of interacting locally with the 
consortium project teams, visiting the implementing institutions and project sites and other 
institutions involved, and of gaining deeper and more direct insight into the progress of the 
project activities.
All project reviews will use the Logical Framework Matrix and its associated annual work 
plans in the project document as the main frame of reference. Review, as monitoring does, 
should in particular examine systematically the indicators of achievement of each of the 
project elements – activity implementation (progress), attainment of specific objective(s), 
outputs, outcome and impacts in relation to the given development objective(s).
Review missions will be conducted by the Bio-Innovate Program secretariat, in cooperation 
with the consortium project leader and representatives of the TAC as appropriate.
The aim of the TAC review is to assess whether the project progress is in accordance with 
the work plans, and to provide recommendations and approve any change in actions which 
would enhance the success of the project.
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The Bio-Innovate Program may also launch specific financial review missions with the 
purpose to improve insight in the actual financial situation i.e. expenditures, liquidity, or to 
help to overcome problems with the financial management. 
Conduct of TAC meetings and review missions
The TAC will meet once or twice each year to review ongoing projects in terms of progress 
in implementation. The date at which meetings are to be held should be determined after 
consultation among all the concerned parties by the Bio-Innovate PMO. The Program 
manager can call special TAC meetings to tackle urgent issues requiring immediate 
attention.
All project monitoring and review, both by the lead executing institution and by the Bio-
Innovate PMO, as well as by the TAC, will use the LFM and its associated work plan as the 
main frame of reference. 
The Bio-Innovate Project Monitoring and Review Missions (PMRM) consist of a TAC 
meeting and a project site visit. For each ongoing project regardless of its size, a PMRM 
should be carried out at least once a year (pre-projects will generally not be visited). In 
principle, each PMRM should include a project site visit; in cases where this is not possible, 
the project site should be visited at least once during the life of the project.
The executing institution is responsible for: 
• submitting an up-to-date consolidated technical and financial progress report four 
weeks before the start of a review mission
• providing adequate transport during the review to the project site and assuring the 
presence of project participants and/or stakeholders at large
• organizing meetings; as members of a review mission shall assess project progress at the 
project site, they need to meet with stakeholders/project participants, verify pilot set-up 
and performance and the allocation and condition of capital items purchased with Bio-
Innovate funds. They will also take photographs for progress documentation and for the 
Bio-Innovate photo library. It is expected that the implementing institutions will make 
the necessary arrangements to make this possible. 
Annex 7 elaborates on the guidelines for field monitoring visits.
7.2.3 Reporting
The Bio-Innovate Program requires that project consortium documents and project partner 
sub-agreements provide for the supply of detailed information by the executing institution. 
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In this section the following reports are introduced:
• inception report       (inception phase)
• yearly plan of activities     (inception phase and implementation phase)
• progress and technical reports   (implementation phase)
• financial reports       (implementation and completion phase)
• completion reports      (completion phase)
When preparing and submitting reports, it may often be useful to illustrate the 
achievements/progress made with the aid of visual materials (graphs, diagrams, pictures, 
etc.).
Inception phase
Immediately after a project has been approved by the Bio-Innovate TAC and funded, the 
Consortium Project Leader should conduct an inception meeting amongst the consortium 
team and collaborating institutions representatives and other stakeholders. The meeting 
shall discuss the necessary arrangements for reporting and resource mobilization for the 
project commencement. 
These include identifying adequate sites for the project, the preparation of an annual work 
plan for the first year (YPA1), defining of roles and responsibilities within the consortium 
projects. The agreements in the meeting and resulting outputs will be incorporated in the 
inception report to be submitted to the Bio-Innovate PMO. The inception meeting can be 
classified as a mobilization venue for the implementing institution to satisfy the necessary 
arrangements for project commencement.
The inception report is the formal notification that the project is about to commence. It 
comprises confirmation that all conditions are met, provisions are in place and formalities 
have been concluded for a smooth start of the project implementation. 
The inception report shall contain matters such as:
• confirmation of the commitments from all involved project teams and collaborating 
institutions
• proof of holding the project bank account (separate account or subaccount) in an 
internationally recognized bank
• proposal of assignment of core project activities
• changes since submission of the project document, if any
The inception report has the following appendices:
• a Yearly Plan of Activities for the first year, or detailed work plan
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• copies of any contractual arrangements between implementing institutions and 
suppliers, contractors, etc.
The format for the inception report with the complete table of content is attached as Annex 4.
The consortium project leader will submit the inception report within two weeks after 
conducting the inception meeting. 
If, within three months of the official starting date, the project has not embarked on all the 
planned activities, the executing institution will report to the Bio-Innovate PMO on:
• the reasons for the delay in start-up
• any preparatory activities that are nevertheless under way
• any measures that are being taken, or could be taken, to speed up the start
• any revision of the detailed work plan that appears necessary as a result of the delay
If within a further three months there is still no progress, the executing institution will 
provide another report to the Bio-Innovate Secretariat. The PMO will then draw this to the 
attention of the TAC at the next TAC meeting and at the Bio-Innovate-Sida Annual Review 
Meeting.
Implementation phase
Yearly Plan of Activities (YPA)
One of the major challenges in project planning is that the ‘radius of foresight’ hardly ever 
corresponds to the ‘radius of action’. That is to say, the longer the duration of a project 
phase, the more difficult it is to correctly assess whether the activities of subsequent years 
are realistically planned. For that reason, planners have introduced the notion of a ‘rolling 
plan’ i.e. a list of the subsequent yearly plans of activities. YPAs are required for all the Bio-
Innovate supported projects for the projects’ implementation period.
The YPA is the annual operational plan for the implementation of the project. The YPA 
should present the coming operational year in greater detail than in the project document. 
It should be based on the results from internal project monitoring, the recommendations 
of external reviewers and the TAC, indicators from the technical progress and financial 
reports for the year prior to the next YPA.
As long as no external evaluation has commended conceptual changes, the outputs of the 
project remain unchanged. In this case, the YPA will remain within the framework of the 
initially defined outputs. Whenever deemed necessary, alternative activities, inputs and 
work plans will be proposed. 
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The format for the YPA is given in Annex 8.
The YPA is prepared, on a yearly basis at the annual project planning meetings, by the 
project leader and his team. The first YPA is attached to the inception report. Before the 
beginning of the next year of project implementation, a new annual project planning 
meeting should be held. The subsequent YPA has to be submitted to the Bio-Innovate 
PMO, together with the annual consolidated progress and financial report, at the latest by 
31st January of each year of project implementation. The Bio-Innovate Program Manager 
approves the YPA upon recommendation of the Bio-Innovate Program TAC, as applicable.
Project Progress Reports
The progress report is the biannual formal and objective account from the executing 
institutions on the project accomplishments, and expenditures incurred in relation to the 
reporting period.
The aim of project progress reports is:
• To ensure that the Bio-Innovate PMO has a clear picture of the extent to which the 
project activities are proceeding according to plan (e.g. tasks which have been started 
or concluded, the percentage of the work carried out). It also justifies the expenditures 
and shows that progress is being made to date in the production of outputs and the 
achievement of specific objectives (information should be based on the results of the 
executing institution’s monitoring of the Project).
• To relate the achievements of resources as financed by the Bio-Innovate funds and any 
other co-funds.
• To justify any request for further instalments of Bio-Innovate funds in terms of timing 
and planned activities and related resource requirements. 
The format for project progress reports is attached as Annex 6.
Consolidated project progress reports on all Bio-Innovate projects under implementation 
shall be prepared by the consortium project leaders and should reach the Secretariat not 
later than 31st January and 30th July in each year of project implementation. The Bio-
Innovate PMO will plan the start of a review mission just after the receipt of the annual 
consolidated progress reports, and before any point in the progress of the project at which 
it is agreed that funds shall be provided to the executing institution for the progress of the 
work, or at any other intervals stipulated in the project sub-agreement.
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Technical reports
Technical reports differ from progress reports in the nature of their content and purpose. 
They register and transfer the results of the work carried out under the Bio-Innovate 
Program research, development and demonstration projects and contain technical and 
scientific data, analysis of the data and the project results. These reports present procedures 
and methodologies adopted, the data established, the results achieved and the conclusions 
reached.
The purpose of the project technical report is to transmit the technical and scientific 
knowledge acquired through the work to the scientific community. This requires that 
the related data be made available in a clear and concise way. Technical reports may also 
be introduced in electronic media. The terminology utilized in the Bio-Innovate project 
technical reports should be appropriate for scientific publications and therefore their 
structure must follow international standards for presentation of technical and scientific 
work. 
Moreover, the technical, methodological and scientific acquired knowledge should be 
‘translated’ in the implications for practice in a way that is digestible and understandable 
for each specific target group. This goal could be achieved by specific chapters in the 
technical reports or by producing a separate series of ’implications for practice’ documents.
The reference part of the technical report may include:
a)  appendix(es), if necessary. The information displayed in the appendix should not be 
essential to understand the discussion of results presented in the main body of the 
report, but should be sufficiently relevant to be included as an appendix.
b)  bibliography, or relevant publications on the theme which may give further insight 
into the project work, should also be presented as an appendix to the main body of the 
report, or as footnotes in the relevant pages of the report.
The format for Project Annual  Technical Reports is given in Annex 9.
Results of various research topics should be presented in individual Technical Reports. 
Technical reports should occur whenever relevant technical results are foreseen. They 
could be interim reports or final reports. The individual final Technical reports should be 
attached to the Completion report.
Financial Report
Half-year financial reports shall be sent to the PMO-ILRI by latest July 30th of every 
project year. Annual project financial reports must be submitted to the PMO-ILRI, latest by 
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January 31st  and must follow the general format provided in Annex 5. 
The biannual financial reports shall be based on the statement of accounts and cover the 
revenue and expenditures as compared to the budget for the entire operation including 
all sources of financing. An approved financial report is a prerequisite for further 
disbursements.
All the collaborating institutions will prepare and channel a signed hard copy as well as a 
soft copy of their financial reports through the PI with a copy to the PMO-ILRI. The PI will 
compile the half-year and final financial project reports for submission to the PMO-ILRI. 
The signed original hard copies will also be directly sent to the PMO-ILRI.
Financial audit report
The Bio-Innovate Program host institution ILRI, is responsible for organizing annual audits 
of the Bio-Innovate consortium projects by an external, independent and qualified auditor. 
If requested by ILRI, the audit shall also cover the six months financial progress reports 
of the Bio-Innovate projects. ILRI reserves the right for performance of any independent 
additional audits, follow-ups and financial reviews and the respective implementing 
institutions shall cooperate on this exercise.  
The Project sub-agreement requires the executing institution to submit to the consortium 
project leader, with a copy to Bio-Innovate PMO, an audited financial statement in addition 
to the financial information in the project progress reports. The financial audit report 
consists of the statement of the auditor accompanied by and referring to:
• the opening balance
• the expenditure incurred against each head of the project budget including cumulative 
receipts and expenditures to date, separately for Bio-Innovate budget and counterpart 
budget components, (actual financial statement)
• any income earned or accruing
• the closing balance for the project accounts, distinguishing between the funding 
provided by Bio-Innovate, the funding provided by the executing institution and the 
funding provided by any other sources
To facilitate a centralized audit, the implementing institution shall on a biannual basis 
submit ORIGINAL payment vouchers and receipts accompanying biannual financial 
reports. The terms of reference for the audit shall be approved by ILRI. The cost of the audit 
shall be paid by ILRI from the Bio-Innovate Program budget. The audit shall be carried out 
in accordance to international standards.
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The auditor shall submit an Audit Memorandum or a Management Letter which shall 
contain the audit findings made during the audit process. It shall also state which measures 
have been taken as a result of previous audit reports, audit memorandums and or 
management letters and whether measures taken have been adequate to deal with reported 
shortcomings.
Audited financial reports are required:
• annually, within three months after the end of the financial year for projects with Bio-
Innovate budget.
• within four months after the completion of the project.
• at any other time which may exceptionally appear to the Bio-Innovate Secretariat to be 
necessary.
Completion phase
Upon completion of the Project, the executing institution shall make an early assessment of 
the outcome(s) and report to the Bio-Innovate PMO in a Completion report.
Completion report
The completion report summarizes the activities, inputs and expenditures, achieved 
outputs and objectives, during the entire implementation phase and highlights particularly 
the most critical differences between planned and realized project actvities using the 
original project document as a reference. The report reflects in retrospect on the project 
identification process, the set objectives and the chosen implementation strategy. To that 
end, the consortium project leaders will organize together with stakeholders an internal 
evaluation shortly before the completion of the project.
The purpose of this report is to record all the relevant information regarding the 
consortium project which should be kept as ’institutional memory‘. The completion report 
will be used as the basis for the Secretariat’s reports to the TAC and Sida on completed 
projects. 
The format for completion reports is given in Annex 10.
The completion report is the final formal report summarizing, upon project completion, 
all planned activities versus their actual implementation, establishing the impact and 
the expected sustainability of the project in the post-project period and presenting the 
lessons learned.
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The consortium projects leaders will
• organize an internal evaluation with all stakeholders shortly before the completion of 
the project. 
• submit the project completion report within three months of project completion. 
A project is officially closed when the Bio-Innovate TAC has accepted the technical 
completion report. The financial closure is marked by the acceptance by the Bio-Innovate 
Program Manager of the final audit and by the refunding of any unused funds and disposal 
of capital goods by the executing institution.
If it is decided subsequently to arrange an ex post evaluation, or such an evaluation has 
already been specifically provided for in the project agreement, the completion report 
will be one of the inputs provided to such an evaluation, which will be carried out in 
accordance with the guidelines on project evaluation presented in section 7.3 of this 
manual.
Special reports
If at any time the Executing Institution discerns that achievement of the project specific 
objective(s) is significantly endangered by unexpected external events or by failures in 
any part of the detailed work plan which the project team is not able to rectify, it shall 
immediately report the situation to Bio-Innovate PMO with as clear an analysis as possible, 
together with its recommendations.
The Bio-Innovate Secretariat will then normally start a special review to assess the situation 
together with the consortium project leader, and with the representatives of TAC as 
appropriate. If funding is earmarked, it will also promptly report the situation to Sida. Such 
special reports shall normally be in the same form as the project progress report.
7.3 Project evaluation
The guidelines and instructions presented in this section are addressed to Bio-Innovate 
Program’s project evaluators. They provide orientation for organizing the evaluation 
process as well as guidance for elaborating the project evaluation report.
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The purpose of an evaluation is to guide or advice on the further implementation of the 
evaluated project and/or on the formulation and implementation of future projects. 
The merit and added value of external evaluations lie in its neutral/objective judgment.
Project evaluation differs basically from project monitoring and reviews. While monitoring 
and reviews are concerned mainly with the progress of the project as originally designed 
(progress in the work plan implementation, appropriate use of funds, application of norms 
and standards both in technical and administrative aspects, etc.), evaluation looks beyond 
the constituent elements of the project, to the validity of its design and to its impact.
Reference for the evaluation is the project document and any changes which might have 
been approved formally during the course of the implementation, as well as reports from 
previous evaluations. Evidence of such changes should be found in YPAs and progress 
reports.
Evaluation is a tool to be applied selectively. It will neither be automatically applied to 
every Bio-Innovate supported project nor at every stage of the project cycle. Since it is 
almost as costly to evaluate small projects as large ones, it will be more cost-effective to 
focus on the latter. The emphasis of the evaluation may vary according to the stage of the 
project midterm or ex post evaluation, see sections 7.3.2 and 7.3.3 below.
Evaluators
The Bio-Innovate Program supported projects midterm and ex post evaluations will be 
undertaken by a team of a maximum of three independent experts, selected by the TAC. 
The evaluation team may be assisted by two or three experts from the project(s) appointed 
by the consortium project leader and the Bio-Innovate Program Manager.
The terms of reference (TOR) for the consultants should be in line with the contents of the 
expected evaluation report (prescribing the scope and focus, methodology, lessons learned 
and findings/ recommendations). 
Evaluation is the systematic and objective collection of information, on the spot 
assessment and analysis of the validity, design, appropriateness, performance and the 
impact of the project.
7.3.1 Concepts and definitions
General
BIO-INNOVATE   Manual  on Standard Operating Procedures
44
The findings of the external evaluation mission are presented in a Project Evaluation 
Report. (See format in Annex 11.)
The evaluation team should report its findings to Sida through the Bio-Innovate endorsed 
by TAC. The Secretariat should ensure that lessons learned, both positive and negative, are 
made available to its partners.
7.3.2 Midterm evaluation
Midterm evaluation is the systematic and objective collection of information, on the 
spot assessment and analysis of the validity, design, appropriateness, performance and 
the impact of the Project during its implementation stage.
The purpose of midterm evaluations is to draw conclusions, guide or advise on all factors 
relevant for the further implementation of the project, including any necessary revision of 
project design based on experiences of the project implementation.
The emphasis of a midterm evaluation will be on the analysis of the objective data which 
indicate project progress: inputs allocation; implementation of activities; achievement 
of outputs; progress towards achievement of the specific objective(s) and whether this 
progress is contributing to the achievement of the development objective as predicted. The 
Logical Framework Matrix will be useful to check whether the original project design is still 
valid, or whether it should be changed in the light of changing circumstances and greater 
knowledge.
The project document and reports from previous evaluations, if available, as well progress 
reports and YPAs serve as reference for the evaluation.
Midterm evaluations will be carried out in circumstances when:
• there are problems in project implementation, upon request from either the Bio-Innovate 
Program secretariat, the TAC or Sida, as appropriate
• the need for midterm evaluation was foreseen at the early stage of project 
implementation
The midterm evaluation report is submitted for consideration to the TAC. 
The project evaluation report resulting from midterm evaluation is intended to 
summarize the information gathered, the findings of the mission, its conclusions and 
recommendations, to provide evidence on the key evaluation elements and to register 
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its results. The report should not be more than 30 pages, format A4, typed in space 2. 
Relevant information, data and documents, which should be kept in a file for eventual 
future consultation, will be included as an appendix to the report. It may also be useful, in 
appropriate cases, to illustrate aspects of the report by visual means (e.g. pictures, figures, 
graphs...).
Evaluators
At least two independent consultants will be engaged to conduct the midterm evaluation. 
The TOR for the external consultants shall be in be in line with the contents of the expected 
project evaluation report prescribing the scope and focus, methodology, lessons learned 
and findings/recommendations. The independent consultants to conduct midterm 
evaluation are selected by the Bio-Innovate Program secretariat in consultation with the 
TAC and Sida.  
Ideally these consultants have relevant experience in agricultural/environmental 
biosciences innovation and or biosciences policy in eastern Africa. 
7.3.3 Ex post evaluation
Ex post evaluation is the systematic and objective collection of information, on the 
spot assessment and analysis of the validity, design, appropriateness, performance 
and the impact of the project after its completion, with the intent to establish the 
extent to which it achieved its objective, its degree of effectiveness and efficiency, as 
well as its sustainability.
The purpose of ex post evaluations is to learn lessons and to draw conclusions for future 
projects. The ex post evaluation should establish the extent to which the results, in terms 
of outputs, achieved objectives, impact and sustainability of the project intervention, have 
been achieved and draw conclusions and recommendations for similar interventions in the 
future. The project document and reports from previous evaluations as well as adjustments 
reported in progress reports and YPAs serve as reference for the evaluation. The completion 
report should be given due consideration as it contains valuable fact analysis and 
recommendations.
The scope of the ex post evaluation
Experience has shown that in many cases the TOR of ex post evaluations requires the 
evaluation team to assess all aspects of a project from its inception to its completion 
regarding administrative and financial matters, organization, communication, consultation 
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and cooperation, technical matters, effectiveness and impact, relevance to Bio-Innovate 
Program, etc. The task is to identify reasons for successes and failures. The execution 
requires a well-balanced team with sufficient time to undertake the task.
Separate assessments on financial issues, audit reports should be continued. Occasionally, 
more detailed financial assessments, including justification of budget items, and use of the 
resources may improve budget estimates and promote stronger financial discipline. Some 
projects may appear to have not served their purposes fully. In those cases the ex post 
evaluation team should also try to assess the extent to which failure could have been 
foreseen during the appraisal of the project proposal based on the information contained 
by the project document. This aspect of the evaluation could help strengthen the process of 
appraising future project proposals.
Thematic evaluations
Ex post evaluations could be executed for the Bio-Innovate thematic area consortium 
projects i.e. consortium projects within the same theme such as thematic area 1 and 2, 
consortium projects addressing adaptation to climate change in agriculture and the 
environment in eastern Africa, as well as in thematic area 3 and 4 focusing on innovation 
incubation and bio-resources innovation policy analysis in eastern Africa, respectively. The 
advantage of this approach is that consortium projects may be compared with each other, 
resulting in:
• more robust analysis of strong and weak factors influencing performance and impact
• direct insight in the usefulness for Bio-Innovate Program and Sida to continually 
support such projects in eastern Africa
The added value of ex post evaluations
What may be expected from an ex post evaluation in addition to the wealth of information 
already made available through critical analysis, reviews and internal evaluations and 
documented in progress reports and completion reports as well as evaluation reports? Most 
of these documents present accurate achievements, differences between anticipated outputs 
and realized outputs, availability and use of resources. They contain analysis, lessons 
learned (or still to be learned) conclusions and recommendations.
The merit and added value of the external ex post evaluations lies not only in its 
neutral/objective judgement and experience but also in the timing. Following a project’s 
completion, it gives a fair judgement on the impact and sustainability of the project.
The Bio-Innovate agreement requires the Secretariat to prepare a document on completed 
pre-projects and projects for TAC review. The TAC will decide upon the necessity of ex post 
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evaluation on the basis of the document prepared by the Secretariat which will include a 
mention of the financial resources available for ex post evaluation. The TAC may decide to 
engage independent consultants to conduct ex post evaluation for a specific project or for a 
thematic group of projects.
7.3.4 Evaluation process, framework and other considerations
The evaluation process is broadly the same, independent of whether it refers to a midterm 
or an ex post evaluation. But the outputs of each one will vary somewhat as a function of 
the project phase. The orientations presented hereafter apply to both types of evaluation.
The analytical evaluation process
The key stages of project evaluation are:
i) Clarification of project design
 The evaluation process starts with the analysis of the project document to reach a 
consensus among the evaluation team/experts regarding the project content and 
intention, the necessary and available background information and other relevant 
aspects.
ii) Analysis of project design
 Following the phase of clarification of project design, the next task of the project 
evaluators is to perform a critical analysis of its elements with the intent of:
• evaluating the origin of the project and project formulation process.
• evaluating the rationale of the project, i.e. the relevance of the specific objective and the 
appropriateness of the implementation strategy.
• establishing the appropriateness of the project elements. This includes the evaluation of 
the linkages between activities and outputs, between outputs and specific objective(s) 
and between specific objective(s) and the development objective.
• establishing the success probability of the project. This includes evaluating the factors 
which will influence or have influenced the achievement of the outputs and specific 
objective(s), outcome and impact of the project, the risks involved, and whether these 
risks can be (or could have been) reduced by changes in design. It is particularly 
important to have a closer look at the effectiveness of cooperation and participation.
 If the project is being evaluated for the first time, the survey by the expert team will also 
include a thorough analysis of:
• the local conditions and situation which prevailed in the field prior to the project 
intervention and at the time of the evaluation
BIO-INNOVATE   Manual  on Standard Operating Procedures
48
• the existing working environment related to the project’s (proposed) activities
• the expectations of the target beneficiaries and the existing arrangements to ensure their 
cooperation
• the existing institutional and project team capabilities of the implementing institution
• the likely social and economic benefit of the project
 To carry out such a survey it is necessary to plan carefully the visits and interviews 
at least one month beforehand. Account should be taken of the relevant portions of 
the guidelines, for ensuring participation of end users in the project cycle, and the 
guidelines to take into account the environmental and socio-economic impact of the 
projects. 
iii) Group review and interpretation of findings
 The next phase following project analysis is a group review of the information gathered, 
involving the evaluation team and the project team. Its purpose is to reach conclusions 
which are as realistic as possible and to ensure that the findings of the evaluation are 
agreed by all interested parties. The review should happen not only at the end of the 
evaluation mission; whenever intermediate conclusions are reached they should be 
discussed by the group to allow full participation and a common understanding of 
the issues underlying the project implementation. It should be stressed, however, 
that it will be on the final group review that the final conclusions will be reached and 
recommendations put forward regarding project design and project steering.
iv) Project evaluation reporting
 The data collected by the evaluation team and its findings will be registered in a project 
evaluation report, designed to record the relevant information gathered in the process 
and its conclusions and recommendations.
The evaluation framework
The analytical process of project evaluation will refer always to an existing project 
document. The evaluation framework is provided by the project document and 
any changes which might have been approved formally during the course of the 
implementation, as well as reports from previous evaluations. Evidence of such changes 
should be found in YPAs and progress reports. A useful form to be employed in the 
clarification of the project design and in the analysis of the linkages of the project elements 
is the LFM of the project document. It should be used by the evaluation team to summarize 
the project design and to orient the clarification and the analytical processes.
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The concept underlying project design is that by providing certain inputs, activities will be 
implemented and will produce outputs. The achievement of these outputs should lead to 
the accomplishment of the specific objective(s) of the project, which will in turn contribute 
to the achievement of the broader development objective. A direct relationship exists 
between the project’s specific objective(s) and the fundamental problems indicated in the 
project identification phase - the enunciation of the specific objective(s) is, or should be, the 
converse of the problem to which the project is addressed. 
Together with this vertical logic - Activities-Outputs-Specific Objective(s)-Development 
Objective - there is a horizontal logic related to the measurement of project progress 
and to the external factors which influence its success. The measurement of progress is 
possible through objectively verifiable indicators, which have been established in the LFM. 
Assessment of the indicators should provide evidence that leads two or more evaluators 
to the same conclusion. The external factors are taken into account as possible risks to the 
project and are made explicit as assumptions which presume success at each level of the 
project elements.
The Bio-Innovate Program requires that before starting field missions, project evaluators 
should be thoroughly acquainted with it.
Annex 12 contains a checklist of issues which may help an evaluation mission team to carry 
out their evaluation. Evaluators do not necessarily need to address all the issues but focus 
on those which fit their TOR.
7.3.5 Special considerations
i)  Preparing the evaluation
 It is recommended that the consortium innovation and policy project leader should 
have at least one month to prepare for the evaluation of the project. This period should 
be sufficient for the project team to organize the necessary information and the logistics 
involved in the conduct of the evaluation mission.
 The Bio-Innovate Secretariat shall contact the consortium project leader with the intent 
of jointly establishing the evaluation procedures and the work plan, including a list 
of the institutions to be visited, persons to be interviewed, dates and local support 
to be provided. The related information, as well as copies of the relevant documents 
available, should be transmitted to whoever will participate in the evaluation mission. 
The mission team should preferably organize a joint process of clarifying project design 
in order to share experiences and to have a common understanding of terminology and 
procedures.
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ii) Coordination of the evaluation
 The Bio-Innovate PMO emphasizes the collaborative nature of the evaluation mission 
and the greatest possible participative involvement of the project teams and financial 
officers from the concerned implementing institutions. One or two representatives of 
the local institutions, especially of the executing institution, should be a member of the 
mission while other representatives participate as much as possible in the evaluation 
process, including in the formulation of its conclusions. If, however, the executing 
institution does not agree with the evaluators’ conclusions its own separate suggestions 
and recommendations should also be duly recorded in the project evaluation report.
 The Bio-Innovate Program Manager should make sure that the work proceeds in a 
spirit of cooperation and not of competition. Past experience has shown that greater 
participation occurs when a cooperative spirit prevails in the evaluation process, and 
that the validity of its results and conclusions depend very much on the participative 
and cooperative aspects of the evaluation.
iii) Work plan and consultation
Work plan content
 The work plan should include the following elements:
• A list of issues and questions to be addressed. In the light of limited time and funds, 
the questions should specifically address issues contained in progress reports and 
completion reports which need further clarification and analysis or which have not 
been covered by these reports.
• A list of the tasks to be completed, the project team members responsible for each one 
and its dates of completion.
• The probable sources of information for each set of issues and questions. The criteria 
to be adopted for the quality control of the information to be gathered, to ensure the 
reliability and validity of the data collected.
• An explanation of how the information and the data to be gathered will be analyzed 
and used to reach conclusions (evaluation design, etc.)
• The evaluation mission agenda, with the institutions to be visited and the list of 
persons to be interviewed.
Work plan drafting process
Before any evaluation field work begins, and after careful review of the relevant project 
file documents, the Bio-Innovate PMO representative should develop a draft work plan 
with the intent of achieving the results established in the mission’s TOR. It is advisable 
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that all parties involved should have knowledge beforehand of such a work plan and 
agree to it.
Consultation
The evaluating missions should make due efforts to consult stakeholders (public sectors, 
end user communities, industry entrepreneurs and private sectors, etc.) properly and 
obtain their points of view. Consultation of individuals and institutions not directly 
linked to the project should also be conducted with the intent of gathering information 
regarding the social and the economic benefit of the project. Issues such as increase in 
productivity, improvement of environmental performance of agro-process industries, 
use of value added products from the project, large-scale use of the innovation by 
small-scale farmers and private sectors, creation of a conducive policy environment by 
applying the relevant policy instruments, etc. may provide relevant indications, direct 
or indirect, of social and economic impacts of the consortium innovation and policy 
projects.
7.3.6 The project evaluation report
The project evaluation report is the formal report by the evaluators on their procedure, 
findings on the key evaluation elements, analysis, conclusions and recommendations. (The 
report should not have more than 30 pages, format A4, typed in space 2). 
Relevant information, data and documents, which should be kept in a file for eventual 
future consultation, should be included as an appendix to the report. When appropriate, 
another appendix will be attached with possible observations of the evaluation report 
contrary to conclusions of the team. It will also be useful, in appropriate cases, to illustrate 
aspects of the report by audiovisual means.
In case of a thematic evaluation, more than one project will be evaluated. The table of 
content of the synthesis report should be the same as the one for the individual projects. 
The chapters should present integrated information. One chapter should be added in the 
synthesis report, i.e. presenting facts and summary of key findings per project.
The outline of contents of a model project evaluation report is given in Annex 11. It 
highlights some basic issues which should be present in the evaluators’ report to guide the 
decision-making process, without the intent of covering all relevant topics. It will be the 
evaluators’ task to include additional issues which they feel may further clarify the project 
proposal, indicate progress of implemented projects or the achievements and impact of a 
completed project.
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7.3.7  Involvement of the donor, the National Councils for Science and 
Technology and other stakeholders
Sida, the councils for Science and Technology (S&T) and other stakeholders in the region 
should be involved or consulted in project monitoring and evaluation. Sida and the 
councils for S&T can be invited to attend TAC meetings and other monitoring visits to 
ascertain the progress of work and provide policy directions to the projects. Likewise 
stakeholders to benefit from the Bio-Innovate supported innovation and or policy projects 
should be part of internal and external monitoring and reviews conducted by the lead 
executing institution/PI and the Bio-Innovate Secretariat.
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8.1 Criteria for suspension
In cases where any violations of the project agreement becomes apparent, or where it 
appears that the conditions surrounding the project have changed to such an extent that, in 
the opinion of the Bio-Innovate Program Manager, the successful completion of the specific 
project is unlikely, the Bio-Innovate PMO in consultation with the TAC may, by written 
notice, suspend all further disbursements of funds pending a review.
8.2 Procedure for suspension
The Bio-Innovate Program Manager may suspend disbursement of the implementing 
institution’s funds to the project if they are being used contrary to the project document or 
in cases of fraud, waste, neglect or mismanagement. The Program Manager will provide 
to the Bio-Innovate-ILRI and Sida at its next annual meeting a report for its consideration. 
Bio-Innovate-ILRI and Sida shall take appropriate action on such a report and they may, 
by special consideration, terminate sponsorship of the project. The Bio-Innovate PMO will 
then formally inform the implementing institution of the decision to suspend the project.
8.3 Effects of the suspension
If Bio-Innovate funding of the project is suspended the executing institution shall not 
incur any further expenditures on activities, financed by such funds unless and until 
such funding is resumed, except with the previous written approval of the Bio-Innovate 
Program Manager. The executing institution shall keep all assets and values previously 
funded by Bio-Innovate for the project in safe custody, and shall give notice immediately to 
any subcontractor whose services are being paid for from Bio-Innovate Program’s funds to 
suspend activities as soon as possible, so as to minimize the cost to the project.
Section 8
Project suspension
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8.4 Criteria and procedure for lifting the suspension
The implementing institution can request lifting of a project suspension if it is satisfied 
that the project task leader/team has satisfactorily addressed the reasons for suspension 
and is ready to resume project operations. Bio-Innovate-ILRI in consultation with Sida can 
then decide to lift the suspension upon recommendation of the TAC and the Bio-Innovate  
Secretariat.
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9.1 Criteria for project termination
In accordance with article 14 of the ‘Bio-Innovate projects sub-agreement and financial 
rules relating to projects’, the Bio-Innovate Program may, by written notice, terminate its 
approval and funding of the project, in particular in cases where it is satisfied that the 
following criteria have been violated:
a) The financial resources provided for the project are being misapplied to an extent which 
compromises the fulfilment of the objectives of the roject.
b)  The technical means and/or personnel being used for the implementation of the project 
are being misapplied to an extent which compromises the fulfilment of the objectives of 
the project.
c)  Its continued approval and funding no longer serve the objectives of the project.
9.2 Procedure for project termination
Based on the criteria for project termination, the Bio-Innovate PMO will present to the 
ILRI and Sida during its Annual Review Meeting a proposal for termination of a project. 
The Bio-Innovate-ILRI-Sida by special vote can terminate such project based on the 
recommendation of the Bio-Innovate Program Secretariat. The executing institution will be 
informed by the Bio-Innovate Program Manager of the decision to terminate a project.
9.3 Effects of project termination
In case of a decision to terminate Bio-Innovate ILRI and Sida approval and funding the 
project shall stop operations upon receipt of the termination letter from the Bio-Innovate 
PMO and the unused part of the resources contributed by the Bio-Innovate Program to the 
project shall be returned to the Bio-Innovate-ILRI together with a final audited statement 
within three months after the date of termination.
Section 9 
Project termination
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10.1 Completion report and post-project sustainability
Upon completion of the project, the lead executing institution shall make an early 
assessment of its outcomes and accomplishments and submit to the Bio-Innovate Program 
a completion report. The completion report is the final project report summarizing, upon 
project completion, all planned project elements versus actual implementation, as well as 
the impact and the expected sustainability of the project in the post-project period, focusing 
particularly on the most critical differences between planned and actual implementation 
and lessons learned. The completion report summarizes the activities, inputs and 
expenditures, achieved outputs and objectives, during the entire implementation phase and 
highlights differences between planned and realized project elements using the original 
project document as reference. The report reflects in retrospect on the project identification 
process, the set objectives and the chosen implementation strategy.
Such a completion report will be used as the basis for the Bio-Innovate Program 
Secretariat’s reports to the TAC and Sida on completed projects. If it is decided 
subsequently to arrange an ex post evaluation, or such an evaluation has already been 
specifically provided for in the project agreement, the completion report will be one of the 
inputs provided to such an evaluation, which will be carried out in accordance with the 
guidelines on project evaluation presented in this Manual for project monitoring, review, 
reporting, and evaluation (Section 7.0 above). A model template for the completion report is 
presented in Annex 10 of the manual.
10.2  Technical report(s)
The executing institution shall submit to the Bio-innovate Program the results of various 
research, development, and demonstration topics as technical reports. The necessary 
technical reports shall be specified in the project document and project agreement as to 
their topic, scope, and dates of submission.
Section 10
Project completion
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The contents of a technical report are technical and scientific in nature. It presents 
procedures and methodologies adopted, the data established, the results achieved and the 
conclusions reached. The purpose of such a report is to disseminate to end users and other 
stakeholders the technical and scientific knowledge acquired through the Bio-Innovate 
Program supported projects. The dissemination of information requires that the related 
data be made available in a clear and concise way. Technical reports may also be presented 
as digital files installed at and downloadable from the Bio-Innovate website. 
10.3 Field verification of outputs and achievements
Both the Bio-Innovate Program secretariat and the executing institutions should conduct 
field verification of outputs and achievements of a project as part of their review, 
monitoring, and evaluation functions. It is particularly crucial at completion stage of the 
project cycle to validate accomplishments and impacts indicated in the completion report 
and technical reports. They can use field reconnaissance observations, sampling, and 
interviews with key stakeholders on the project site, and review of pertinent project reports.
The findings and recommendations can provide the executing institution with the 
opportunity for corrective measures before a project formally closes or continue with 
another phase or follow-up projects.
10.4 Role of the Bio-Innovate Technical Advisory Committee
The Bio-Innovate TAC is responsible for the evaluation of the requirements for project 
completion before presenting to Sida for decision to formally declare such project as 
completed. They can initiate a further evaluation review by the Bio-Innovate Program 
Secretariat on the stated accomplishments and impacts of the project or an audit by the Bio-
Innovate financial officer if necessary to assess supporting documents for disbursements.
10.5 Technical and financial requirements for project completion
A project can be considered completed upon review and approval by the respective TAC 
committee members of the completion report and final audited statement submitted by the 
executing institution and or verified from a centrally audited report.
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The Bio-Innovate Program Secretariat initiates the closure of the account of the project in 
the financial records of Bio-Innovate PMO after: 
i) approval of the completed project by Bio-Innovate TAC
ii) receipt of satisfactory final audited financial statements
iii) receipt of the unused funds from the executing institution (if any)
The remaining funds in the completed project account of Bio-Innovate Project (if any) 
would comprise of remaining unused funds from: 
a) the Bio-Innovate project monitoring and evaluation budget and/or 
b) other remaining funds not used by the executing institution
Within the financial records of the Bio-Innovate Program, the account of the completed 
project is closed after the transfer of these unused funds from this account to ILRI: 
a) unused Bio-Innovate project monitoring and evaluation funds to the ‘pooled ex post 
evaluation account’ subject to the consent of Sida for the subsequent financing of the 
regular program for ex post evaluations as approved by the TAC 
and 
b) the other remaining funds to the Sida account. (Usually these funds are subsequently 
reallocated by Sida  for financing other approved projects.)
Section 11
Project closure
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BIO-INNOVATE CONSORTIUM PARTNER SUB-AGREEMENT
Between
THE INTERNATIONAL LIVESTOCK RESEACRH INSTITUTE (ILRI)
P.O.Box 30709 Nairobi 000100, Kenya
And
[The executing institution full name] (Abbreviation) 
{POSTAL ADDRESS, CITY, COUNTRY}
Hereinafter referred to as ‘The Parties’
On the implementation of Bio-Innovate Consortium Project 
[Consortium Project number - ‘Consortium Project title’]
Dated: 
WHEREAS:
A. The International Livestock Research Institute (hereinafter referred to as ILRI) is 
entrusted to manage and host the Bio-Innovate Program funds for participating 
Eastern African Institutions as part of the Agreement between ILRI and Sida 
concerning the Bio-Innovate Program.
B. Upon the recommendation of the Bio-Innovate Technical Advisory Committee 
(hereafter referred to as TAC), ILRI in consultation with Sida has approved the 
Consortium Project  [Consortium Project number - ‘Consortium Project title‘], 
(hereinafter referred to as ‘the Consortium Project’), and ILRI will make available 
to the name of the executing institution (hereinafter referred to as {Abbreviation 
of implementing institution}) funds amounting to a total of United States dollars 
Annex 1
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amount in words only (US$ XXX,XXX.XX) for the purpose of implementing the 
afore-mentioned Consortium Project as provided for in this Sub-Agreement for the 
period  from  date to date.
C.  {Abbreviation of implementing institution} is one of the implementing partners 
for this Consortium Project. This Sub-Agreement signed by individual Consortium 
Members governs the role and responsibilities of ILRI and {Abbreviation of 
implementing institution} in implementation of the Project.
D. The Consortium Members will collectively sign the ‘Bio-Innovate Consortium 
Agreement’ with ILRI which governs the relationship and responsibilities of the 
Consortium Members and the Management of Intellectual Property under the Bio-
Innovate Program.
NOW THEREFORE the parties hereby agree as follows:
ARTICLE 1
SCOPE OF THE CONSORTIUM PROJECT
1.0 The Consortium Project Document attached hereto as Appendix 1, shall form part of 
this Agreement, and shall govern the scope and details of the Consortium Project.
ARTICLE 2
EXECUTION OF THE CONSORTIUM PROJECT
2.0 {Abbreviation of implementing institution} shall be responsible for executing the 
Consortium Project in accordance with the Consortium Project Document and any 
supplementary arrangements which may be agreed between the parties.
2.1  {Abbreviation of implementing institution} shall implement the Consortium 
Project in a manner consistent with the Bio-Innovate Program and Sida rules and 
procedures applying to Bio-Innovate Consortium Projects. 
2.3 {Abbreviation of implementing institution} shall do its utmost to ensure that the 
Consortium Project is implemented on schedule, within the agreed budget, and in 
such a way as to achieve its objectives.
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ARTICLE 3
FUND DISBURSEMENTS
3.1 {Abbreviation of implementing institution} shall open and maintain a separate bank 
account for the Consortium Project fund with a bank of high reputation. Any interest 
the funds may yield shall be separately accounted for in the financial reporting and 
utilized within the Consortium Project after approval by the Bio-Innovate Program 
Management Office (PMO) in conformity with Sida requirements. Interest not 
utilized within the Consortium Project shall be repaid to Sida through ILRI.
3.2 Requisitions for funds for the Consortium Members shall be routed through the 
principal investigator (PI) for approval and subsequent submission to the Bio-
Innovate PMO. 
3.3 Funds for the Consortium Members shall be sent directly to their specified 
institutional bank accounts upon receiving approval from the Consortium Project PI.
3.4 Requests for disbursement of funds shall be accompanied by a consolidated technical 
progress report and a consolidated financial report on the utilization of funds 
previously disbursed indicating the use of at least 75% of the previous disbursement. 
3.5 Disbursements will be made in United States dollars to {abbreviation of  
implementing institution}, in accordance with the following disbursement schedule:
(a) Upon signature of this Sub-Agreement and receipt of an official request from 
{abbreviation of implementing institution} Bio-Innovate PMO shall transfer 
the first 50 % installment from the year 1 budget.
(b) The second  50% installment from the year 1 budget after receipt by Bio-
Innovate PMO of the first consolidated biannual Consortium Project technical 
progress and financial reports from the Consortium PI for the reporting period 
August – December in accordance with the procedures of the Bio-Innovate 
Program, and a justified request for the payment in terms of the approved 
Consortium Project budget commensurate with the Yearly Plan of Activities, in 
light of implementation thus far, for the period to which funds shall relate.
(c) The third installment, 50% from the year 2 budget after receipt by the Bio-
Innovate PMO of the second consolidated biannual Consortium Project 
technical progress and financial reports from the Consortium PI for the 
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reporting period January – June in accordance with the procedures of the 
Bio-Innovate Program, and a justified request for the payment in terms of the 
approved Consortium Project budget commensurate with the Yearly Plan of 
Activities, in light of implementation thus far, for the period to which funds 
shall relate.
(d) The fourth installment, 50%  from the year 2 budget after receipt by the Bio-
Innovate PMO of the consolidated third biannual Consortium Project technical 
progress and financial reports from the Consortium PI for the reporting 
period July – December in accordance with the procedures of the Bio-Innovate 
Program, and a justified request for the payment in terms of the approved 
Consortium Project budget commensurate with the Yearly Plan of Actions, in 
light of implementation thus far, for the period to which funds shall relate
(e) The fifth installment, 50% from the year 3 budget after receipt by the Bio-
Innovate PMO of the consolidated fourth biannual Consortium Project 
technical progress and financial reports from the Consortium PI for the 
reporting period January – June in accordance with the procedures of the 
Bio-Innovate Program, and a justified request for the payment in terms of the 
approved Consortium Project budget commensurate with the Yearly Plan of 
Activities, in light of implementation thus far, for the period to which funds 
shall relate
(f) The sixth and final installment, 50%  from the year 4 budget after receipt by 
the Bio-Innovate PMO of the consolidated fifth biannual Consortium Project 
technical progress and financial reports from the Consortium PI for the 
reporting period July – December made in accordance with the procedures 
of the Bio-Innovate Program and a justified request for the payment in terms 
of the approved Consortium Project budget commensurate with the Yearly 
Plan of Activities, in light of implementation thus far, in order to successfully 
complete the Consortium Project. 
3.6 The Bio-Innovate PMO may withhold the disbursement, wholly or in part, if 
substantial deviations from the Consortium Project plan and budget occur, if reports 
are not delivered as agreed or if the Consortium Project progresses unfavorably in 
terms of the objective(s) or in any other important respect. The Bio-Innovate PMO 
shall however, initiate discussions with {abbreviation of implementing institution} 
before taking such a decision. 
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ARTICLE 4
UTILIZATION OF FUNDS
4.1 The funds provided by the Bio-Innovate Program under this Agreement shall be 
used solely to meet those direct Consortium Project activities which are itemized in 
the approved budget of the Consortium Project Document.
4.2 Funds allocated to one budget heading or subheading item shall not be transferred to 
another without the express prior approval of the Bio-Innovate PMO. All materials, 
equipment, supplies and services purchased using Bio-Innovate funds shall be used 
exclusively for the implementation of the Consortium Project.
4.3 Budget reallocations of not more than 10% on each budget line shall be allowed 
without consultation. However, reallocations in the approved budget of more than 
10% on each budget line shall be agreed upon, in advance and in writing between 
the parties and with explicit approval by the Bio-Innovate PMO. 
4.4 Significant changes in the scope and content of the Consortium Project activities 
must be approved by the TAC and recorded in minutes.
4.5 The funds are available up to and including the specified Project completion date. 
If an extension is required, an application for this purpose stating the grounds for 
the extension shall be submitted to the Bio-Innovate PMO three months prior to 
the specified Project completion date. The extension must be approved by both 
{abbreviation of implementing institution} and the Bio-Innovate PMO. 
4.6 {Abbreviation of implementing institution} shall take every precaution against any 
unauthorized use of the funds provided to it by the Bio-Innovate Program, and 
shall at all times keep up-to-date and full accounts of the expenditures incurred by 
the Consortium Project. The Bio-Innovate PMO may at any time request a financial 
statement from {abbreviation of implementing institution}, accompanied by certified 
balances of the Consortium Project’s bank accounts, and such a request shall be 
promptly complied with. 
4.7 Funds remaining unutilized after the completion of the Consortium Project shall 
be remitted to Bio-Innovate - ILRI  within two months of the specified Project 
completion date, unless otherwise agreed.
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ARTICLE 5
REPORTING, MONITORING AND EVALUATION
5.1 {Abbreviation of implementing institution} shall submit to the Consortium PI 
technical and financial reports as follows: 
(a) For the period January – June both Project technical progress and financial 
reports latest by 30th June.  
(b) For the period July – December both Project technical progress and financial 
reports latest by 31st December.  
5.2 The Consortium PI shall submit to the Bio-Innovate PMO the consolidated 
Consortium Project technical and financial reports as follows:  
(a) For the period January – June the consolidated Consortium Project technical 
progress and financial reports latest by 31st July.
(b) For the period July – December the consolidated Consortium Project technical 
progress and financial reports latest by 31st January. 
5.3 The Consortium PI shall submit to the Bio-Innovate PMO [on an annual basis] Yearly 
Plans of Activities.
5.4 The Consortium PI shall submit to the Bio-Innovate PMO a completion report not 
later than three months after the completion of the Consortium Project. 
5.5 The progress and technical reports [as well as the Yearly Plans of Activities] shall be 
prepared in accordance with the reporting formats established in the ‘Manual on 
Standard Operating Procedures for Bio-Innovate Program Supported Projects’.
5.6 {Abbreviation of implementing institution} shall, upon request, make available to the 
Bio-Innovate Program Secretariat any information relevant to the implementation, 
financing or follow-up of the Consortium Project. 
5.7 The Consortium PI shall promptly inform the Bio-Innovate PMO of any delay, event 
or obstacle that may significantly endanger the implementation of the Consortium 
Project.
5.8 Monitoring and review meetings [and TAC meetings] will be convened at the request 
of the Bio-Innovate Program Manager with the participation of the Consortium PI 
and representative of the {abbreviation of implementing institution}. 
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ARTICLE 6
PROCUREMENT
6.1 {Abbreviation of implementing institution} shall be responsible for the purchasing of 
the equipment as approved in the budget. Equipment shall remain the property of 
{abbreviation of implementing institution}.
6.2 Procurement of goods, works and services shall be performed in accordance with the 
procurement rules of Sida. No offer, gift or payment, consideration or benefit of any 
kind that would be construed as illegal or corrupt practice, shall be accepted, either 
directly or indirectly, as an inducement or reward for the award or execution of Sub-
Agreements financed within this Consortium Project. At the request of either of the 
Parties, consultation shall be held on any matter relating to procurements under this 
Agreement.
6.3 The Bio-Innovate PMO may perform procurement audits. {Abbreviation of 
implementing institution} shall on request provide the Bio-Innovate PMO with all 
necessary documentation.
6.4 {Abbreviation of implementing institution} shall maintain an up-to-date inventory of 
all assets/equipment procured with the Project funds. 
ARTICLE 7
TRAVEL, SUBSISTENCE AND ACCOMMODATION
7.1 Utilization of funds for travel expenses and field allowances shall be in accordance 
with the approved budget line in the Consortium Project document, and approved 
institutional policies.
ARTICLE 8
AUDIT
8.1 Bio-Innovate - ILRI  shall perform centralized audits of the submitted biannual 
financial reports of the Consortium Project. The cost of the audit shall be borne by 
the Bio-Innovate Program budget. The financial year of the Consortium Project shall 
be from 1 January to 31 December of each year.
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8.2 To facilitate the auditing process, {Abbreviation of implementing institution} 
shall submit all Original Vouchers together with the financial statements to the 
Bio-Innovate PMO on a biannual basis not later than 31st January and 31st July 
in each year during the implementation of the Consortium Project. This will be a 
prerequisite for the disbursement of further Consortium Project funds. {Abbreviation 
of implementing institution} shall fully co-operate with and assist the auditor in the 
auditing mission.
8.3 Audit findings shall be communicated by the Bio-Innovate PMO to {abbreviation 
of implementing institution}. A management response shall be submitted by 
{abbreviation of implementing institution} within a reasonable time.
8.4 Audits shall be performed by duly recognized independent auditors appointed by 
Bio-Innovate-ILRI in consultation with Sida. 
8.5 The Bio-Innovate Program Secretariat may visit any facilities and sites included in 
the Consortium Project to examine the accounts and records, and the equipment 
procured under the Consortium Project.
ARTICLE 9
CONSORTIUM AGREEMENT
9.1 The Consortium Members will sign a Consortium Agreement stipulating the 
terms and responsibilities of each of the Members involved and the regulation and 
ownership of Intellectual Property (IP) in the Consortium Project. 
9.2 The Bio-Innovate PMO reserves the right to withhold Consortium Project funds until 
the Consortium Agreement has been signed by the Consortium Members.  
ARTICLE 10
DISPUTES
10.1 General disputes between Bio-Innovate - ILRI and {abbreviation of implementing 
institution} shall be resolved amicably by the TAC. 
10.2 In the event that the TAC fails to resolve a dispute, an arbitrator agreeable to all 
parties involved shall be appointed to resolve the dispute. Legal disputes that cannot 
be settled amicably between Bio-Innovate - ILRI and {abbreviation of implementing 
institution} under this Sub-Agreement shall be finally settled by arbitration in 
accordance with the Rules of the International Chamber of Commerce. 
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ARTICLE 11
SUSPENSION
11.1 Notwithstanding the provisions of Article 3  of this Agreement, where any violations 
of this Agreement becomes apparent, or where it appears that the conditions 
surrounding the Consortium Project have changed to such an extent that in the 
opinion of the Program Manager the successful completion of the Consortium 
Project is unlikely, the Bio-Innovate PMO may by written notice suspend all further 
disbursements of funds pending a review.
11.2 In the event of a suspension {abbreviation of implementing institution} shall 
immediately cease any further expenditure using Project funds, except with the 
previous written approval of the Bio-Innovate Program Manager. {Abbreviation 
of implementing institution} shall hold all assets of the Consortium Project in safe 
custody, and shall give notice immediately to any subcontractors to suspend their 
activities immediately, so as to minimize further cost to the Consortium Project.
ARTICLE 12
TERMINATION
12.1 In accordance with rules and procedures of the Bio-Innovate Program relating to 
Consortium Project implementation and use of funds, the TAC may, by written 
notice, terminate funding of the Consortium Project, in particular in cases where it is 
satisfied that:
(a) The funds provided for the Consortium Project are being misapplied to an 
extent which compromises the fulfillment of the objectives of the Consortium 
Project. 
(b) The conditions for Consortium Project implementation could not be met due 
to circumstances beyond the party’s control.
(c) Sida suspends or stops funding the Bio-Innovate Program. 
12.2 Upon termination, {abbreviation of implementing institution} shall refund to ILRI 
any unexpended or uncommitted balance of funds advanced. The institution shall 
then submit full financial and technical reports on all activities up to the termination 
date within 30 days of the termination date.
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ARTICLE 13
MODIFICATION OF THE AGREEMENT
13.1 This Agreement may be modified by written mutual consent between the Parties.
IN WITNESS THEREOF the undersigned, duly appointed representatives of the parties 
have signed on behalf of the respective Parties to this Consortium Partner Agreement in 
three originals on the dates indicated below. 
For ILRI                                           For {abbreviation of implementing institution}
_______________________________________  ________________________________
Director General          {CEO of the implementing institution}
For ILRI            For {Name of the of implementing institution}
Dated: ___________________________               Dated: _________________________
Enclosures:
(i) The Consortium Project Document (Appendix 1)
(ii) The Consortium Project Technical Progress Report Format (Appendix 2) 
(iii) The Consortium Project Financial Report Format (Appendix 3)  
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BIO-INNOVATE CONSORTIUM AGREEMENT
To Govern the Relationship, Responsibilities and the Management of Intellectual 
Property under the Consortium
Dated: xxxxx2011
PREAMBLE 
This Consortium Agreement is entered into by and between Bio-Innovate - ILRI  and the 
Consortium Partners namely: 
• {list names of consortium partners} 
• {list names of consortium partners} 
• {list names of consortium partners} 
Hereinafter referred to individually as ‘Party’ or ‘Member of the Consortium’, and 
collectively as the ‘Parties’ or ‘the Consortium’.
WHEREAS
1. The Bio-resources Innovations Network for Eastern Africa Development (Bio-
Innovate) Program is a multidisciplinary competitive funding mechanism for 
biosciences and product-oriented innovation activities in Eastern Africa. Its mission 
is to create and promote bio-resource-based innovation systems in Burundi, Ethiopia, 
Kenya, Rwanda, Tanzania and Uganda for sustainable utilization and integration 
of the innovations into Eastern Africa’s economic development processes. It is 
supported by a grant from the Swedish International Development Cooperation 
Agency (Sida). It builds on previous investments, achievements and experiences 
from the Sida-supported Bio-Innovate Program  and other regional initiatives. 
Bio-Innovate will focus on delivering new products through bioscience innovation 
Annex 2
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systems involving a broad range of actors, including scientists, private sector, policy 
makers, NGOs and other practitioners. It will use modern biosciences to improve 
agriculture and conserve the environment through enhancing crop productivity 
and resilience to climate change in small-scale farming systems and improving the 
efficiency of the agro-processing industry to add value to local bio-resources. It will 
also develop sound policies for commercializing products from biosciences research 
and investigate innovative delivery systems. Bio-Innovate is managed by and hosted 
at ILRI.
2. The Parties to this Consortium Agreement have individually entered into a 
Consortium Partner Sub-Agreement with Bio-Innovate - ILRI  to undertake their 
component of the Bio-Innovate Consortium Innovation Project entitled ‘Title of the 
project’ (hereinafter referred to as the ‘Consortium Innovation Project’). The project 
is further described in the Consortium Project Document (Appendix 1). 
THE PARTIES AGREE AS FOLLOWS:
ARTICLE 1
DEFINITIONS
1.1 ‘Consortium’ means the Consortium formed by Parties to this Agreement.
1.2 ‘Bio-Innovate Network Institutions’ means the institutions comprising the Bio-
Innovate network, which are listed in Appendix 2 of this Consortium Agreement.   
1.3  ‘Consortium Partner Sub-Agreement’ means the agreement executed by ILRI 
and each of the Parties for implementation of their component of the Consortium 
Innovation Project.
1.4 ‘Bio-Innovate Program Management Office’ (PMO) means the program management 
team as constituted and hosted at ILRI .
1.5 ‘Intellectual Property Management Committee’ means the Committee to be 
established by the TAC of the Bio-Innovate Program to oversee the management of 
intellectual property matters of the Bio-Innovate Consortium Projects.
1.6 ‘Intellectual property’ means patents, copyrights and other rights which may exist 
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in any part of the world in know-how, inventions and discoveries leading to new 
technologies useful in agriculture or the environment.
1.7 ‘Innovation’ means the introduction of new ideas, products and or processes, goods, 
services, and practices which are intended to be useful.
1.8 ‘Letter of Agreement’ means a letter from the national competent authority 
designated to oversee access requirements for genetic resources within a particular 
country.
1.9 ‘Project Teams’ means the Principal Investigators and all consortium project 
members including scientists, technicians, or students or their universities or 
institutes who participate in the Consortium Innovation Project activities.
1.10 ‘Project Term’ means the specified duration of the Consortium Innovation Project as 
provided in this Consortium Agreement. 
ARTICLE 2
PURPOSE
2.1 This Consortium Agreement governs the roles and the responsibilities of each of 
the Parties and the management of Intellectual Property (IP) in the Consortium 
Innovation Project. 
ARTICLE 3
INNOVATION PROJECT MANAGEMENT
3.1 The roles of the Parties in implementation of the Consortium Innovation Project 
Activities are defined in the Consortium Project Document (Appendix 1) 
 {Insert name of institution} hereinafter referred to as {abbreviation of the institution}) 
shall be the lead institution in implementing the {name of the Project}. As Lead 
Institution, {abbreviation of the institution} has the delegated role of managing 
and directing the Consortium Innovation Project to completion. The Principal 
Investigator will be responsible for day-to-day coordination of the Consortium 
Innovation Project on behalf of the Parties and will report to the Bio-Innovate 
Program Management Office (PMO).
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3.2 The Bio-Innovate PMO shall be responsible for ensuring that the Consortium 
Innovation Project is reviewed and evaluated to monitor progress. All decisions that 
can potentially alter the course of the Consortium Project or that are binding to the 
Consortium shall be made by the PMO. Such decisions shall not be binding to the 
Consortium unless they are made in writing and carry the signatures of all Parties. 
ARTICLE 4
INTELLECTUAL PROPERTY MANAGEMENT COMMITTEE
4.1 The Bio-Innovate PMO in consultation with the Bio-Innovate TAC will establish 
an Intellectual Property Management Committee (IPMC) consisting of one 
representative from each of the Bio-Innovate Network Institutions. The decision 
about who should represent a Bio-Innovate Network Institution in the IPMC rests 
solely with that Institution. A Bio-Innovate Network Institution which wishes to 
change its IPMC representative shall inform the Bio-Innovate PMO of that decision 
in writing. An IPMC representative may delegate his or her authority to a designee 
upon written notice to the Bio-Innovate PMO. 
4.2 All matters relating to intellectual property management under the Consortium 
Innovation Project shall be the responsibility of the IPMC.
4.3 The IPMC shall conduct its affairs on an as-needed basis to address matters of 
mutual interest and concern to the Consortium. The IPMC may convene either in 
person, by telephone conference call, or in any other manner mutually agreed to. 
All matters will be discussed in good faith and the IPMC shall arrive at positions or 
decisions through consensus in the first instance. If no consensus is arrived at, the 
IPMC shall vote and the majority shall prevail. The quorum shall be at least two-
thirds.
4.4 On matters other than negotiating the terms of a license agreement for any 
Intellectual Property, consistent with Article 5.1 of this Consortium Agreement, 
each Bio-Innovate Network IPMC representative shall represent his/her institution, 
unless the Parties to this Consortium Agreement agree otherwise. 
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ARTICLE 5
PUBLICATIONS 
5.1 The Innovation Project is expected to generate outputs in the form of project reports 
and scientific publications consistent with the Project Work Plan. All publications 
will contain appropriate recognition of each Party’s contributions, clearly indicating 
that they are the outcome of a collaborative undertaking between the Parties, and 
other collaborators as appropriate. Arrangements for authorship, style, editing, peer 
review, decision on publication format, and distribution will be agreed jointly on 
a case by case basis. Due credit and recognition shall be given to the Bio-Innovate 
Program-ILRI and Sida for their support of the activities. 
5.2 Sida shall have the right to copy and distribute in a suitable form any reports and 
studies that have been submitted by ILRI on behalf of the Bio-Innovate Program to 
Sida.
5.3 The Consortium shall be entitled to jointly publish, present or use any material 
relating to or arising from the Consortium Project provided always that each Party 
agrees to the content and mode of presentation of such publication. Each Party 
may use the published material for its own instructional, research or publication 
objectives.
5.4 Any proposed publication or presentation relating to the Project shall be submitted 
to the Parties for review and comment at least thirty (30) days prior to submission 
for publication or presentation.
5.5 Notwithstanding anything contained in Clause 5.4 above, a Party shall not publish, 
present or use any material relating to or arising from the Project against the written 
objection of any other Party.
5.6 In the event that a proposed publication or presentation contains Intellectual 
Property which needs protection, the Party proposing such publication shall, upon 
receipt of a written request of the other Party having identified such Intellectual 
Property (IP) within the thirty (30) day review period , delay the publication or 
presentation for a maximum of an additional sixty (60) days to allow for the filing 
of the relevant application(s) for the protection of the relevant Intellectual Property 
therein. This period shall be extended if the filing of the application is delayed by 
factors beyond the control of the Party responsible for filing the application.
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ARTICLE 6
INTELLECTUAL PROPERTY
6.1 It is recognized that the activities of the Bio-Innovate Program will predominantly 
generate public goods for use in African agriculture and the environment. Wherever 
possible, the results of the Consortium Innovation Project will be made available 
as global or regional public goods. However, there may be some instances where 
the Bio-Innovate Program TAC considers that some form of intellectual property 
protection would aid commercialization and hasten the delivery of the products 
of the research to smallholder producers and small-scale enterprises in Africa, 
at affordable prices and in a sustainable manner. In such cases, the TAC will 
make a recommendation to the Bio-Innovate Program-ILRI and Sida to allow the 
Consortium Partners to pursue opportunities to protect and commercialize IP 
resulting from the Project. 
6.2 Each Consortium Member must notify the PMO where it considers that a need for 
commercialization exists, so that the issue is forwarded to the TAC for expert advice. 
6.3 Each Member of the Consortium shall require all of its scientists, employees or 
students conducting research under the Consortium Innovation Project to assign 
their rights in any Intellectual Property conceived during the Consortium Innovation 
Project to the Member of the Consortium. Nothing in this clause shall be interpreted 
to require MSc and or PhD students to assign copyright in their thesis. 
6.4 The Members agree that inventorship shall be determined on the basis of having 
made a contribution to the invention.
6.5 Title to Intellectual Property shall be held jointly between all Parties.
ARTICLE 7
LICENCES
7.1 In the event that IP developed during the Consortium Innovation Project activities 
becomes subject to a licensing arrangement, the Parties shall designate one Member 
of the Consortium (the ‘Designated Member’) who shall take the lead in negotiating 
the license. The Designated Member may negotiate the license using his/her 
in-house capacity or may engage the services of a negotiator, provided that the 
Designated Member shall keep the Consortium informed of all decisions. The IPMC 
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representative of the Designated Member shall act as the liaison in the negotiations, 
liaising between the IPMC and the negotiating team.  The terms of any license 
agreement shall be agreed to by all Parties prior to the execution of the license, which 
license shall be signed by all the Parties. 
7.2 All royalty payments made by a licensee pursuant to the license agreement shall 
be shared among the Parties equitably taking into account the contribution by each 
Party on a case by case basis.
7.3 Each Member shall be solely responsible for calculating and distributing to its 
respective innovator(s) any consideration  due to the innovator(s) according to its 
institutional Policy.
ARTICLE 8
PROJECT CONTACT PERSONS
8.1 The Principal Investigator and the Co-investigators will be the official contact 
persons for all matters relating to the Consortium Innovation Project. Neither the 
Principal Investigator  nor any Co-Investigator has authority to make any binding 
commitments on behalf of the Consortium.  
ARTICLE 9
PRE-EXISTING TECHNOLOGY
9.1 Not withstanding anything in this Consortium Agreement, each Member of the 
Consortium shall own its respective intellectual property that it has developed 
outside the framework of the Consortium Innovation Project exclusively.
9.2 Any Party with information about pre-existing technology or contractual 
arrangement which can potentially hinder commercialization of resulting IP shall 
inform the Consortium.  
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ARTICLE 10
CONSORTIUM INNOVATION PROJECT SCIENTISTS
10.1 The Parties acknowledge that their scientists may each be entering into a consulting 
relationship directly with the Bio-Innovate Program. Nevertheless this Consortium 
Agreement shall not be deemed to relieve a scientist from complying with policies 
and procedures regarding such consulting relationships as established by the Party 
employing such a scientist.
10.2 A Party who employs a scientist who wishes to take a sabbatical leave during the 
Research Term shall take reasonable steps to secure compliance with the Consortium 
Agreement by the scientist.
 
10.3 Should a Party utilize the services of another organization in the conducting 
components of the Innovation Project, the Party shall ensure that the terms under 
which the services are rendered shall not contradict the terms of this Consortium 
Agreement.
10.4 In the event that a Researcher or Principal Investigator of the Collaborating 
Institutions leaves the Project, such institution will nominate a replacement for 
approval by the PMO.
ARTICLE 11
EXCHANGE OF GENETIC MATERIALS
11.1 The Parties shall, whenever exchanging biological material, conclude a Material 
Transfer Agreement (MTA) setting out the terms and conditions upon which the 
biological material, from either country, described in the project document will be 
transferred, held, or applied by the recipient party. The MTA should be signed by 
the Parties’ authorized signatories at the collaborating institutions. A model MTA is 
attached to the Consortium Agreement. 
11.2 The PMO reserves the right to withhold project funds until such a Material Transfer 
Agreement has been signed by the parties in the event of envisaged exchange of 
genetic materials and a copy submitted to the PMO.  
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ARTICLE 12
RELATIONSHIP BETWEEN PARTIES
12.1 The Parties do not intend by entering into this Consortium Agreement to create a 
corporation, partnership, joint venture or any other form of separate legal entity, and 
nothing in this Consortium Agreement shall be interpreted in a manner inconsistent 
with this. The employees or agents of each Party shall continue to be employees or 
agents of that Party and shall not be considered for any purpose to be employees or 
agents of any other Party.
ARTICLE 13
DISPUTE RESOLUTION
13.1 Given the cooperative and collaborative nature of the Consortium Innovation Project 
that the Parties are conducting under the Consortium Partner Sub-Agreements, the 
Parties acknowledge that the potential termination of this Consortium Agreement 
could create great difficulties for the Consortium and the Bio-Innovate Program, and 
could have serious consequences on the Innovation Project. The Parties therefore 
agree to use their reasonable best efforts to avoid having any dispute result in 
the termination of either this Consortium Agreement or the Consortium Partner 
Sub-Agreement.
13.2 General disputes between ILRI and the involved institutes shall be resolved amicably 
by the TAC. In the event that the TAC fails to resolve a dispute, an arbitrator 
agreeable to all parties involved shall be appointed to resolve the dispute. Legal 
disputes that cannot be settled amicably between ILRI and the involved institutes 
under the Contract shall be finally settled by arbitration in accordance with the Rules 
of the International Chamber of Commerce. 
13.3 This Consortium Agreement shall be construed and interpreted under the laws of 
Kenya. The obligations of any one Party shall be evaluated under the law of the 
Country in which the Party is incorporated.     
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ARTICLE 14
TERM AND TERMINATION
14.1 The term of this Consortium Agreement shall be [insert duration of the Project]. 
However, to the extent that any Intellectual Property Rights or licenses are procured 
as provided under this Consortium Agreement, the Agreement shall remain in effect 
until the expiration of such rights or such license.
14.2 The Members may terminate this Consortium Agreement by giving the other 
members six (6) months notice.
14.3 If Bio-Innovate - ILRI  terminates the Consortium Partner Sub-Agreement with 
a Member of the Consortium that Member shall continue to be a Party to this 
Consortium Agreement only for purposes of management of jointly owned 
Intellectual Property and licenses accrued as a result of its prior involvement in 
the Innovation Project. In the event of such a termination, the remaining Parties 
shall continue to be Parties to this Consortium Agreement and shall negotiate any 
amendments to this Consortium Agreement, necessitated by such termination in 
good faith. 
ARTICLE 15
MISCELLANEOUS PROVISIONS
15.1 The Consortium Agreement may be amended by mutual agreement of the Parties. 
Such amendments shall not be binding unless they are in writing and signed by 
personnel authorized to bind each of the Parties. No Party may assign any of its 
rights or obligations arising under this Consortium Agreement without the express 
prior written consent of the other Parties, which consent shall not be unreasonably 
withheld.
15.2 A failure by any Party to exercise its rights under this Consortium Agreement 
shall not preclude that Party from subsequent exercise of such rights and shall not 
constitute a waiver of any other rights under this Consortium Agreement unless 
stated to be such in a writing signed by an authorized representative of the said 
Party and distributed to the other Parties.
15.3 If any provision of this Consortium Agreement or any provision of any document 
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incorporated by reference shall be held invalid, such invalidity shall not affect the 
other provisions of this Consortium Agreement which can be given effect without 
the invalid provision, if such remainder conforms to the requirements of applicable 
law and the fundamental purpose of this Consortium Agreement, and to this end the 
provisions of this Consortium Agreement are declared to be severable.
15.4 This Consortium Agreement contains all the terms and conditions agreed upon by 
the Parties. No other understandings, oral or otherwise, regarding the subject matter 
of this Consortium Agreement shall be deemed to exist or to bind any of the Parties 
hereto. This provision does not affect the validity of the Consortium Partner Sub-
Agreement license agreements, or any related agreements, exhibits, and appendices 
entered into between the Parties and Bio-Innovate - ILRI .
15.5 All notices required to be given under this Consortium Agreement shall be given 
and addressed to the executing Offices of the Parties by confirmed delivery of email 
or post.  
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AGREED TO, UNDERSTOOD AND ACCEPTED BY:
ILRI               {Name of Institution} 
Authorized Officer: ____________________  Authorized Officer: ___________________
Title: _________________________________  Title: ________________________________
Sign: _____________________________ ____  Sign: ________________________________
Date: _________________________________  Date: ________________________________
{Name of Institution}         {Name of Institution}   
Authorized Officer: ____________________  Authorized Officer: ___________________
Title: _________________________________  Title: ________________________________
Sign: _____________________________ ____  Sign: ________________________________
Date: _________________________________  Date: ________________________________
Enclosures:
Model Material Transfer Agreement (MTA)
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BIO-INNOVATE MODEL
MATERIAL TRANSFER AGREEMENT
Dated: XXXXXX
THE PARTIES 
This Material Transfer Agreement (MTA) will facilitate and govern the terms of the transfer 
of materials between: 
A. [INSERT NAME & ADDRESS] (‘ Provider’) 
 AND
B. [INSERT NAME & ADDRESS] (‘Recipient’)
PREAMBLE
The Parties are jointly undertaking an Innovation Project entitled:
{INSERT THE TITLE OF THE PROJECT}
(‘Innovation Project’), a project under the Bio-Innovate Program funded by the Swedish 
International Development Cooperation Agency (Sida), through the International Livestock 
Research Institute (ILRI) where the Program is hosted.
The Parties have executed a Consortium Agreement to facilitate collaboration in 
undertaking the Innovation Project Activities. 
THE PARTIES THEREFORE AGREE AS FOLLOWS:
1. DEFINITIONS 
1.1 ‘Parties’ shall mean the institutions named here above. 
1.2 ‘Biological Material’ means any material of a plant, animal or microorganisms 
Annex 3
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or from another origin containing units of heredity and/or any other biological 
material which is considered as proprietary by the Provider. 
1.3 ‘Material’ means [insert description of the material to be transferred; biological name 
and quantity].
1.4 ‘Non-biological Material’ means any material other than Biological Material which is 
considered as proprietary by the Provider.
1.5 ‘Provider’ means provider of a Biological or Non-biological Material and may 
be the country providing a genetic resource collected from in situ or ex situ 
sources including populations of both wild and domesticated species according 
to the principles of the Convention of Biological Diversity. Provider may also be 
an institution providing Non-biological Material or a part of a plant, animal or 
microorganisms or other origin containing units of heredity. 
1.6 ‘Recipient’ means receiver of a Biological or Non-biological Material provided by the 
Provider. 
1.7 ‘Intellectual Property Management Committee (IPMC)’ means the committee 
established by the Technical Advisory Committee (TAC) of the Bio-Innovate 
Program to oversee the management of intellectual property matters of the 
Bio-Innovate projects, and whose responsibility is described in the Consortium 
Agreement. 
 
2 AUTHORISED REPRESENTATIVES
2.1 Each Party will designate persons as the duly authorized representative (‘Authorized 
Representative’) for the purposes of implementing this MTA. The Authorized 
Representative shall be responsible for ensuring that all institutional, national and 
international laws and procedures in force relating to the exchange of Biological and 
Non-biological Material are respected by the respective Parties.  
3 OWNERSHIP
3.1 Material exchanged in accordance with this MTA including any Material contained 
or incorporated in modifications, wherever located, shall at all times be the property 
of the Provider and shall not be used by, or transferred to third parties without the 
knowledge, consent and written authorization of the Provider.
3.2 The ownership of any new intellectual property derived from Material transferred 
under this MTA shall be governed by the terms of the Consortium Agreement. 
All modifications of Material developed jointly by the Parties shall be owned as 
provided for in the Consortium Agreement. 
3.3  The Recipient shall grant the Provider on any modification a non-exclusive, world-
wide, royalty-free right to use for its internal research purposes only. For avoidance 
of doubt, the use granted under this subclause is for non-commercial purposes only. 
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4 CONDITIONS FOR USE OF MATERIAL 
4.1 Unless otherwise agreed between the Parties, any Material transferred under this 
MTA is to be used solely for the Innovation Project. 
4.2 If the Recipient wishes to use the Material in any other way, other than described 
in the Innovation Project, the Recipient must seek written authorization from the 
Provider.  
4.3 Each Party shall comply with the terms of this MTA and shall ensure that its staff 
including but not limited to scientists, technical staff as well as students are aware of, 
and comply with the provisions of this MTA. 
4.4 All material that falls under Annex 1 of the International Treaty of Plant Genetic 
Resources for Food and Agriculture shall be exchanged using the Standard Material 
Transfer Agreement as defined under that treaty. 
5 CONFIDENTIAL INFORMATION
5.1 ‘Confidential Information’ means all confidential or proprietary information or 
materials directly relating to the Innovation Project howsoever disclosed by any 
Party, whether disclosed in writing, orally, or visually, including, without limitation, 
inventions, methods, plans, processes, specifications, know-how, compounds, 
business plans, financial statements, cost information, or technical information 
relating to the data generated in the Innovation Project.
5.2 The Parties shall hold in confidence, and shall not disclose to any third party other 
than their employees, agents and consultants, any Proprietary and/or Confidential 
Information of the other Party. The Parties shall only disclose Proprietary and/or 
Confidential Information received or generated under this MTA to those of its 
employees, agents and consultants who have a need to know such Proprietary and/
or Confidential Information in the course of the performance of their duties.  
5.3 The obligations specified in Clause 5.1 above shall not apply, and the Parties shall 
have no further obligations hereunder with respect to any Proprietary and/or 
Confidential Information, to the extent that such Confidential Information is:
5.3.1 possessed by a Party, other than through prior disclosure by the disclosing 
other Party, prior to the commencement of dealings between the Parties as 
evidenced by the Parties’ written records and which was not acquired directly 
or indirectly from the other Party 
5.3.2 in the public domain at the time of disclosure
5.3.3 already published or available to the general public after disclosure, otherwise 
than through a breach of this Agreement
5.3.4 obtained by a Party from a third party with a valid right to disclose such 
Information, provided that the said third party is not under a confidentiality 
obligation to any of the Parties or any other third party
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5.3.5 independently developed by employees of a Party which had no knowledge of 
the other Party’s information as shown by relevant documentary evidence
5.3.6 required to be disclosed via a competent legal process
5.4 The Parties shall protect, store and handle the Proprietary and/or Confidential 
Information in such a way as to prevent unauthorized disclosure and unwarranted 
access, acting always in accordance with prudent commercial practice and having 
utmost regard for the sensitivity of the Proprietary and/or Confidential Information.
5.5 The above obligations of confidentiality shall survive the expiry or termination of 
this MTA and continue for a period of five years after the date of termination. 
6 DURATION OF THE AGREEMENT 
This Agreement shall be valid until the end of the Innovation Project. The following 
Paragraphs shall survive the termination of the Agreement: Paragraphs 3, 4, and 5. 
7 TERMINATION
7.1 Unless otherwise agreed, this MTA shall terminate at the expiry of the Innovation 
Project provided that the following shall apply to any Material exchanged under 
each specific MTA. 
7.1.1  The Parties shall remain bound to each other by the terms applicable to the 
Material obtained in the pursuance of the purposes of this MTA and any 
modifications thereof.
7.1.2 The Parties shall discontinue their use of the Material and return any 
remaining Material to the Provider; where such return is not practical the 
Parties shall destroy such Material.
7.1.3 If for any reason, any of the Parties wishes to terminate this Agreement before 
the completion of the Innovation Project each of the Parties agree that they 
shall give written notice of six months (6) to the other Parties so as to enable 
the completion of ongoing research. Such written notice shall be provided 
to each of the designated Parties’ representatives that are signatories to this 
Agreement.
8 SETTLEMENT OF DISPUTES
Any disputes which arise between Parties during the performance of MTA shall be settled 
as provided for in the Consortium Agreement. 
9  MISCELLANEOUS
9.1 The Parties acknowledge that the Material provided in pursuance of the purpose 
of this Agreement may have characteristics that are unknown or difficult to 
determine and which may be potentially hazardous. NONE OF THE PARTIES 
MAKES WARRANTIES, EXPRESS OR IMPLIED, AS TO THE SAFETY, 
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QUALITY, VIABILITY OR PURITY OF THE BIOLOGICAL MATERIAL, OR ITS 
MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.
9.2 No variation or amendment to this MTA shall be effective unless in writing and 
signed by authorized representatives of each member.
9.3 If any provision of this MTA shall be held to be invalid, such invalidity shall not 
affect any other provision of this MTA, but the remainder hereof shall be effective as 
though such invalid provisions had not been contained herein.
9.4 Failure by any Party to exercise its rights under this MTA shall not preclude that 
Party from subsequent exercise of such rights and shall not constitute a waiver of 
any other rights under this MTA unless stated to be such in a writing signed by an 
authorized representative of the said Party and distributed to the other Parties. 
AGREED TO AND ACCEPTED BY:
Name of Provider Institution_____________________________________________________
Full Address ___________________________________________________________________
Authorized Officer  ____________________ Principal Investigator ____________________
Title _________________________________ Title ___________________________________
Signature ____________________________ Signature _______________________________
Date _________________________________ Date ___________________________________
Name of Recipient Institution_____________________________________________________
Full Address ___________________________________________________________________
Authorized Officer  ____________________ Principal Investigator ____________________
Title _________________________________ Title ___________________________________
Signature ____________________________ Signature _______________________________
Date _________________________________ Date ___________________________________
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FORMAT FOR THE BIO-INNOVATE PROJECT INCEPTION / 
PLANNING MEETING REPORT 
The inception report is the formal notification that the consortium Innovation and or 
Policy Project is about to commence. It comprises confirmation that all conditions are met, 
provisions are in place and preparations have been concluded for a smooth start of the 
Project implementation. The inception report has the following Appendices:
• Yearly Plan of Activities for the first year (YPA 1) or a detailed Work plan
• Memorandum of Understandings (MoU’s) between the Lead Institution and 
Collaborating partners, if any.
Front cover of the inception report
• inception report
• title of the Bio-Innovate Consortium Project 
• Project number
• name of the Principal Investigator and Lead Institution 
• names of co-Principal Investigators, and other collaborating institutions
• starting date of the Project
• duration of the Project 
• Project costs (US $)
• place and date of the Inception report submission to the Bio-Innovate Program 
Management Office
Table of contents
The inception report contains the following matters:
1) brief description of the planning meeting on the consortium project activities
2) intended commencement date of the Project
Annex 4
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3) proposed project team and related arrangements for starting the project activities
4) clear roles and responsibilities of project team members commensurate with annual 
work plan 
5) proof of availability of adequate office facilities
6) proof of bank account (separate account or subaccount) in internationally recognized 
bank
7) arrangements with collaborating partners as appropriate
8) information on arrangements with consultants (assignment date and duration; selection 
procedure; ToR), as applicable
9) changes since submission/approval of the Project proposal
Appendix 1 YPA with detailed Work plan
Appendix 2 MoU with collaborating Agencies, as applicable
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A B C D E F G H I J
PERIOD Expenditure 
First Period 
Year 1
Expenditure 
Second 
Period
Year 1
Expenditure 
First Period 
Year 2
Expenditure 
Second 
Period
Year 2
Expenditure 
First Period 
Year 3
Expenditure 
Second 
Period
Year 3
Cummulative 
Expenditure 
Totals
Total 
Budget for 
the Entire 
Project 
Period
Budget 
Balance
Total 
Expenditure 
as a %age of 
Total Budget 
{G / H} 
Total Amount Available  -    -    -    -    -    -    -   
Balance at the start of the reporting period  -    -    -    -    -    -   
Project Advance from Bio-Innovate - ILRI  -    -    -    -    -    -    -    -    -   
Interest Income on Bio-Innovate held A/C  -    -    -    -    -    -    -    -    -   
EXPENSES
Code       Category
529520    Field work, Training & Dissemination  -    -    -    -    -    -    -    -    -   
529530    Equipment & Consumables  -    -    -    -    -    -    -    -    -   
529540    Management & Coordination {general}  -    -    -    -    -    -    -    -    -   
529550    Travel  -    -    -    -    -    -    -    -    -   
                  Overhead  -    -    -    -    -    -    -    -    -   
TOTAL EXPENSES  -    -    -    -    -    -    -    -    -   
Balance at the end of the reporting period  -    -    -    -    -    -   
We certify that the above information is a true representation of the project transactions incurred in the                  execution of the above mentioned project and that adequate original supporting documentation for the 
transactions is included for your review and for annual centralized audit at ILRI.                                                                                                                                                                  
Finance Officer
Name …………………………………………….
Signature……………………………………........
Date………………………………………………
Project Coordinator
Name ………………………………………………
Signature …………………………...………………
Date………………………………..….………...…..
Head of Institution
Name ……………………………………………
Signature …………………………...……………
Date………………………………..….……...…..
INSTITUTIONAL PROJECT FINANCIAL REPORT
{TO BE COMPLETED IN US DOLLARS}      
Institution:   
Project Number and Title:
Report Period:   From:   ______ / ________ /_______          To: ______ / ________ /_______
                         Date      Month         Year                    Date         Month       Year
Exchange Rate Used (USD)___________          
FORMAT FOR THE BIO-INNOVATE BIANNUAL FINANCIAL REPORT 
Annex 5
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A B C D E F G H I J
PERIOD Expenditure 
First Period 
Year 1
Expenditure 
Second 
Period
Year 1
Expenditure 
First Period 
Year 2
Expenditure 
Second 
Period
Year 2
Expenditure 
First Period 
Year 3
Expenditure 
Second 
Period
Year 3
Cummulative 
Expenditure 
Totals
Total 
Budget for 
the Entire 
Project 
Period
Budget 
Balance
Total 
Expenditure 
as a %age of 
Total Budget 
{G / H} 
Total Amount Available  -    -    -    -    -    -    -   
Balance at the start of the reporting period  -    -    -    -    -    -   
Project Advance from Bio-Innovate - ILRI  -    -    -    -    -    -    -    -    -   
Interest Income on Bio-Innovate held A/C  -    -    -    -    -    -    -    -    -   
EXPENSES
Code       Category
529520    Field work, Training & Dissemination  -    -    -    -    -    -    -    -    -   
529530    Equipment & Consumables  -    -    -    -    -    -    -    -    -   
529540    Management & Coordination {general}  -    -    -    -    -    -    -    -    -   
529550    Travel  -    -    -    -    -    -    -    -    -   
                  Overhead  -    -    -    -    -    -    -    -    -   
TOTAL EXPENSES  -    -    -    -    -    -    -    -    -   
Balance at the end of the reporting period  -    -    -    -    -    -   
We certify that the above information is a true representation of the project transactions incurred in the                  execution of the above mentioned project and that adequate original supporting documentation for the 
transactions is included for your review and for annual centralized audit at ILRI.                                                                                                                                                                  
Finance Officer
Name …………………………………………….
Signature……………………………………........
Date………………………………………………
Project Coordinator
Name ………………………………………………
Signature …………………………...………………
Date………………………………..….………...…..
Head of Institution
Name ……………………………………………
Signature …………………………...……………
Date………………………………..….……...…..
Grant Code:   Activity Code     Partner Code:
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Activity / Item Who is responsible Consortium level 
Review, Approval 
and Forward to 
PMO-ILRI by
Due Dates Supporting documents to 
accompany the Reports and 
official fund disbursement 
requests
Procedures Explanatory Notes
{1} Biannual Project Technical 
Progress Report 
{2} Biannual Financial Report 
{3} Biannual Official Funds 
Disbursement Request
Implementing 
Institution’s in-country 
Bio-Innovate Project 
team led by PI and Co-
PI(s)
Bio-Innovate 
Consortium 
Project team led by 
Consortium Principal 
Investigator (PI).
30th June 
and 31st 
December 
from the 
collaborating 
institutions 
(Co-PI) to 
the Lead 
Institution 
(PI). 
31st July and 
31st January 
from the Lead 
Institution 
(PI) to PMO-
ILRI
{1} detailed Bio-Innovate 
project ledger print-outs for 
the period
{2} monthly bank statements 
and reconciliations
{3} ORIGINAL payment 
vouchers relating to the Bio-
Innovate project
{4} complete and updated 
assets register for assets 
procured under the Bio-
Innovate project as per the 
Financial Report sheet on 
pages 89-90
{5} official institutional request 
for the next project advance
{6} activity plan for the next 
period approved by the PI
{7} any other support 
documentation as may be 
requested
{1} The institutional Bio-Innovate project 
team will prepare a complete and 
fully signed report using the standard 
Bio-Innovate financial reporting 
format as per the Financial Report 
sheet on pages 89-90. 
{2} All SOFT COPY reports and 
accompanying disbursement requests 
will be forwarded to the consortium 
PI for verification, approval, 
consolidation and subsequent 
submission to  the PMO-ILRI. The 
PMO-ILRI will have a Cc. of the soft 
copy report to the PI. A HARD COPY 
VERSION OF THE FINANCIAL 
REPORTS WILL BE SENT DIRECTLY 
TO THE PMO-ILRI. 
{3} The PMO-ILRI will further review the 
approved reports from the PI. 
{4} The PMO-ILRI will effectuate the 
funds disbursement request for 
satisfactory reports. 
{5} The PMO-ILRI will provide feedback 
on the status of the reports submitted 
including queries for ‘unsatisfactory’ 
reports. 
{6} The partner will provide feedback for 
arising queries.
{7} The partner will confirm and 
acknowledge receipt of funds by way 
of email and a receipt.
{1} Biannual 
reports deal 
with the 
reporting 
of actual 
expenditure per 
category as per 
budget 
{2} Necessary 
additional 
explanatory 
notes on the 
report should 
be provided 
to minimize 
the need to 
generate and 
address queries 
as part of the 
review process.
(3) All expenses 
must be 
adequately 
supported 
and a set of 
the complete 
support 
documentation 
maintained at 
the respective 
institutions.
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Activity / Item Who is responsible Consortium level 
Review, Approval 
and Forward to 
PMO-ILRI by
Due Dates Supporting documents to 
accompany the Reports and 
official fund disbursement 
requests
Procedures Explanatory Notes
{1} Biannual Project Technical 
Progress Report 
{2} Biannual Financial Report 
{3} Biannual Official Funds 
Disbursement Request
Implementing 
Institution’s in-country 
Bio-Innovate Project 
team led by PI and Co-
PI(s)
Bio-Innovate 
Consortium 
Project team led by 
Consortium Principal 
Investigator (PI).
30th June 
and 31st 
December 
from the 
collaborating 
institutions 
(Co-PI) to 
the Lead 
Institution 
(PI). 
31st July and 
31st January 
from the Lead 
Institution 
(PI) to PMO-
ILRI
{1} detailed Bio-Innovate 
project ledger print-outs for 
the period
{2} monthly bank statements 
and reconciliations
{3} ORIGINAL payment 
vouchers relating to the Bio-
Innovate project
{4} complete and updated 
assets register for assets 
procured under the Bio-
Innovate project as per the 
Financial Report sheet on 
pages 89-90
{5} official institutional request 
for the next project advance
{6} activity plan for the next 
period approved by the PI
{7} any other support 
documentation as may be 
requested
{1} The institutional Bio-Innovate project 
team will prepare a complete and 
fully signed report using the standard 
Bio-Innovate financial reporting 
format as per the Financial Report 
sheet on pages 89-90. 
{2} All SOFT COPY reports and 
accompanying disbursement requests 
will be forwarded to the consortium 
PI for verification, approval, 
consolidation and subsequent 
submission to  the PMO-ILRI. The 
PMO-ILRI will have a Cc. of the soft 
copy report to the PI. A HARD COPY 
VERSION OF THE FINANCIAL 
REPORTS WILL BE SENT DIRECTLY 
TO THE PMO-ILRI. 
{3} The PMO-ILRI will further review the 
approved reports from the PI. 
{4} The PMO-ILRI will effectuate the 
funds disbursement request for 
satisfactory reports. 
{5} The PMO-ILRI will provide feedback 
on the status of the reports submitted 
including queries for ‘unsatisfactory’ 
reports. 
{6} The partner will provide feedback for 
arising queries.
{7} The partner will confirm and 
acknowledge receipt of funds by way 
of email and a receipt.
{1} Biannual 
reports deal 
with the 
reporting 
of actual 
expenditure per 
category as per 
budget 
{2} Necessary 
additional 
explanatory 
notes on the 
report should 
be provided 
to minimize 
the need to 
generate and 
address queries 
as part of the 
review process.
(3) All expenses 
must be 
adequately 
supported 
and a set of 
the complete 
support 
documentation 
maintained at 
the respective 
institutions.
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Institution
Project number and title
Project Fixed Assets Register as at: ____________________________
No Asset Description Serial Number Tag No. Date of Purchase        Amount {US$} Title Current Location Condition
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
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No Asset Description Serial Number Tag No. Date of Purchase        Amount {US$} Title Current Location Condition
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
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Consortium Project Title:
Consortium  Project Number:
Technical Progress Report No.____________________
          (e.g. No. 1/2011)
Reporting Period:
From:  _________ / __________/ _________   To: _________ / __________/ __________ 
                  Date          Month          Year               Date        Month    Year
Project Status_____________________________________________________________
Submitted to: Principal Investigator: ____________________________________________
Submitted by: Co-PI / Collaborating Scientist:  ___________________________________
Reviewed and Submitted by Principal Investigator: ______________________________
To: Bio-Innovate PMO 
Submission Date________________________________
Received By: Bio-Innovate PMO: Name __________________Signature______________
Received Date___________________________________________________________
Principal Investigator: (Full names, address and contacts)
Co-Principal Investigators / Collaborating Scientists: (Full names, address and contacts)
Annex 6
FORMAT FOR THE BIO-INNOVATE CONSORTIUM PROJECT 
TECHNICAL PROGRESS REPORT
Bio-resources Innovation Network for Eastern Africa 
Development (Bio-Innovate) Program
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Executive Summary
Provide a brief coverage overview of the report including the progress and achievement to date.
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1. Introduction
Activities overview of the content of the report including the scope set out to accomplish during 
the period as well as collaborating institutions’ work on the consortium project.
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1.1 Project Background
Provide the background and rationale of the project very briefly.
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1.2 Project Objectives
Outline the consortium project objectives as given in the project document.
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2. Project Activities and Progress.
2.1 Description of the work implemented in the period
Provide a brief overview of the work which has been implemented in the period covered by this 
report stressing the relevant results achieved and the possible deviations from the Work plan/
YPA. (If there is not enough space, provide an appendix.)
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2.2 Execution of the Work plan
Provide a review of the original Project’s Work plan and the progress in implementation, by 
reference to the situation at the last date of the period covered by the report.
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2.3 Progress in implementation of the activities
Provide for all the activities, which appear in the Project Document including the changes as 
presented in the Yearly Plan of Activities, the estimated percentage of their implementation and 
the estimated completion date of those which have not been completed at the date of the report.
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2.4 Project Outputs
Describe the progress made during the reporting period towards achievement of the Outputs 
and Outcomes related to the Activities which have already started and show, for the Outputs 
and Outcomes which have already been achieved, the corresponding Objectively verifiable 
indicators using a result-based management matrix given in Table 1 on page 103. (Whenever 
their Means of Verification is supported by documentary evidence, a copy of such a document, 
or the relevant parts of it, should be attached to the Progress Report).
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Table 1: Project Output and Outcome summary following the result-based 
management approach
Output/target Outcome 
(impact thrust)
Measureable indicators
output outcome Achievements to date
Objective # 1:
1.1
1.2
1.3
1.4
Objective # 2: 
2.1
2.2
2.3
2.4
Objective # 3:
3.1
3.2
3.3
3.4
Objective # 4:
4.1
4.2
4.3
4.4
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2.5 Unaccomplished Project Activities
Please outline the planned consortium project activities that were not accomplished within the 
reporting period if any, and give the justifiable reasons for not accomplishing them.
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3. Planned Consortium Project Activities
Provide clear planned consortium project activities for the next reporting period using the 
annual activity program table.
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4. General comments on the overall project progress
Provide comments and quantification of any advance or delay in implementing the Activities, in 
achieving the Outputs or in using the Project’s Inputs, including their causes and expectation 
of the effect if any corrective actions are to be taken. This refers: 
i)  explicitly to any (previously) unexpected events or problems. Were there any events 
or problems that may significantly affect the Project’s implementation schedule, the 
achievement of the Outputs and of the Specific Objective(s), or the Project’s budget? 
ii)  comments on the fulfillment of the assumptions related to the Project’s Outputs and Specific 
Objective(s). Are the assumptions still valid? Have they proven to be true thus far?
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5. Any other supporting information
Please provide by way of appendixes any information relevant to the report that has been 
obtained in the course of project implementation.
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6. Conclusions
Provide the conclusions reached by the Consortium Project team on the state of Project 
implementation, based on the critical analysis of up-to-date progress. Indicate whether progress 
towards achievement of the Project’s Specific Objective(s) is: 
a) on track 
b) slightly but not seriously impeded or
c) seriously endangered.
Please also indicate corrective actions which will be adopted, if any, and whether specific 
support is necessary from the Bio-Innovate Program for solving any problems; whether another 
disbursement of funds of Bio-Innovate is being sought in relation to implementation of the Work 
plan and specify expected expenditures; and indicate with a justification the best period for a 
possible Bio-Innovate PMO monitoring review visit to the implementing institution.
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I the undersigned Project Principal Investigator and or Co-Principal Investigator /
Collaborator declare that all the project information and outputs included in the 
report are unified and up to date.
Name__________________________ Signature________________ Date____________
Declaration
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GUIDELINES FOR BIO-INNOVATE PROJECTS FIELD MONITORING 
MISSIONS
1  General rules regarding Bio-innovate Project     
Monitoring Missions
• A Project Monitoring Mission (PMM) consists of a TAC meeting to deliberate on project 
progress reports and a project site visit.
• For each ongoing project, a PMM should be carried out at least once a year.
• The first PMM should take place within the first year of project implementation.
• Before projects are approved for funding, the Bio-Innovate Secretariat should assure that 
sufficient funds are allocated in the budget for monitoring and ex post evaluation and, if 
appropriate, for midterm evaluation.
• In principle, each PMM should include a project site visit; in cases where this is not 
possible (i.e. remote project sites), the project site should be visited at least once during 
the life of the project.
2 Checklist of activities
2.1 Prior to the Project Monitoring Mission
Both the Bio–Innovate Management Office and the Executing Institution (EI) are 
responsible for a number of activities that should be carried out to ensure a smooth process. 
Below is a checklist for each.
Bio-Innovate Management Office
• Plan the overall schedule (date and venue) of the PMM.
•  Check availability of funds for monitoring in the project budget (obtain ‘fund status 
report’ of the Project from the Management Office).
Annex 7 
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•  Liaise with the EI at least one month in advance of the PMM regarding:
• date
• venue
• language of the meeting
• participants
• required documentation
• agenda
• project site visit, etc.
• Communicate travel arrangements to the EI.
• Review all relevant project documentation:
• Project Document
• Project Agreement and, if appropriate, supplementary agreements between the EI 
and other collaborating scientists
• YPAs
• progress reports including financial statements
• technical reports
• no-objection letters
• minutes of previous PMMs
• correspondence
• Through the review of the documentation, make a preliminary assessment of the 
following aspects:
• whether the project is progressing according to agreed work schedules (YPA) 
(compare actual outputs and activities in Progress Report with that in the Project 
Document, identify problem areas)
• effectiveness of project organization, including the roles and responsibilities of the 
institutions involved, the management structure
• acquisition of capital items (equipment/pilot construction)
• adherence to the subcontract agreement and Bio-Innovate guidelines by the EI 
(Bio-Innovate Guidelines for Consultants, Procurement, Rules & Procedures, 
other Manuals, follow-up actions regarding audit reports, etc.)
• major issues/problems to be followed up at the TAC with a view to develop 
corrective actions (to achieve project objectives as designed in the Project 
Document)
Executing Institution
• Invite participants to TAC meeting.
•  Prepare required documentation.
•  Make logistical arrangements for the meeting and project site visit.
•  Prepare a detailed program of the PMM.
•  Send the following documentation to all participants at least two weeks prior to the 
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TAC meeting:
• Progress report
• Financial report1  
• YPA
• meeting agenda
• any technical reports produced by the project since the last PMM.
•  Send the tentative program of the PMM to the Bio-Innovate PMO for approval.
•  Arrange for airport pick-up and hotel reservations.
2.2 During the Project Monitoring Mission
Active involvement is required from the Bio-Innovate PMO and the Executing Institution 
during the PMM as follows:
a) TAC meeting
Bio-Innovate PMO
•  Review the agenda for completeness.
•  Together with the other members of the TAC, review the following aspects of project 
implementation:
• quality of project planning (Yearly Plan of Operation/Work Plan)
• Project organization, management structure, roles and responsibilities of the 
institutions involved and internal and external coordination mechanisms
• adequacy of project reporting
• activities in relation to progress towards ‘specific objective(s)’ and ‘outputs’ 
achieved
• external factors affecting project implementation
• risks as described in the Project Document including new risks arising during 
implementation
• deviations from the original project design during implementation
• current financial information and audit requirements (identify and seek 
justification for major variations in actual expenditures - from approved project 
fund - compared with the budget components in the Project Document)
• actual counterpart contribution and its adequacy with regard to project 
implementation progress
• acquisition of capital items (pilot construction/equipment)
•  Discuss any matter arising from the assessment with the TAC members and encourage 
and support a participatory problem-solving and decision-making process within the 
TAC.
1 Financial reports should be prepared according to the format in Annex 5.
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•  Verify that mechanisms for ensuring sustainability after project completion are being 
established and, if necessary, assist the TAC in identifying such mechanisms.
•  If appropriate, agree on the timing of a ‘Midterm Evaluation’.
•  Review the draft of the Minutes of the TAC meeting. (Ensure that all matters including 
decisions taken are accurately reflected in the report.)
•  Sign the final version of the Minutes.
Executing Institutions
•  Provide for an adequate meeting room and necessary audio-visual equipment.
•  Appoint a secretary to take notes and to prepare the Minutes of the meeting.
•  Arrangements for the opening of the meeting and presentation of participants.
•  Make presentations on the items listed in the Agenda using audio-visual aids.
•  Assure the timely signature of Minutes by the representative of the Executing Institution 
and the Bio-Innovate Program Manager.
b) Minutes of TAC meetings
•  Minutes should:
• adhere to the meeting agenda
• summarize major topics of discussion and problems encountered
• clearly state any recommendations and/or decisions made
• include approval and adoption of project reports (progress report, YPA/work 
plan, and financial report).
•  The agenda and list of participants should be annexed.
•  Any modifications to the budget approved by the TAC should be annexed.
•  The Minutes should be signed by a representative of the Executing Institution, the Bio-
Innovate Program Manager, and, if appropriate, other members of the TAC.
• The Minutes should be completed and signed before the departure of the Bio-Innovate 
PMO representative.
c) Project Site Visit
Bio-Innovate PMO
•  Assess project progress at the project site.
•  Meet with stakeholders/project participants
•  Verify infrastructure and allocation and condition of capital items purchased with Bio-
Innovate funds.
•  Take photographs with a digital camera for the Bio-Innovate photo library.
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Executing Institution
•  Provide adequate transport to the project site.
•   Assure presence of stakeholders and/or project participants.
2.3  After the Project Monitoring Mission
Bio-Innovate PMO
•  Complete the ‘Mission Report’ and brief ILRI and Sida.
•  Update Bio-Innovate Program project database.
•  Follow up of issues requiring further actions (as highlighted in the Minutes of the 
meeting and in the Mission Report).
Executing Institution
•  Follow up on decisions taken by the TAC, including formally requesting ‘no-
objection’ from the Bio-Innovate PMO to any modifications of activities or the budget 
recommended by the TAC.
Bio-Innovate PMO Mission Report
Staff member: ___________________________________________
Dates: _________________________________________________
Location(s): _____________________________________________
Event(s):
Main activities during the visit:
Major issues/problems encountered:
Supplementary information (other persons met with, issues discussed):
Follow-up to the Mission (who, when, where):
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FORMAT FOR THE BIO-INNOVATE PROJECT ANNUAL WORK 
PLAN/YEARLY PLAN OF ACTIVITIES 
Consortium project team leaders and project teams should develop annual work plans 
during their annual planning meetings. The annual work plan builds upon the results of 
previous project operational years and the conclusions and recommendations for corrective 
actions, as commended by project teams, which should be reflected in the most recent 
Project Progress Report. It is therefore recommended to submit both the Project Progress 
Report and Annual Work plan at the same time. 
Cover page
A. Front side
• Annual Work plan and year for which it is planned
• Title of the Bio-Innovate Consortium Project 
• Project number
• Names of the PI and Co-PIs with full contact addresses
• Starting date of the Project
• Place and date the draft Annual Work plan was submitted to the Bio-Innovate Program
Table of contents
1) Project Progress Report (not for first year)
2) Operational Yearly Program of Activities (max. 6 pages)
2.1  Logical Framework Matrix (LFM) and annual indicators
2.2  Outputs and activities
2.3  Activity plans
Annex 8
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2.4  Indicators and assumptions
2.5  Monitoring and reporting
3) Personnel planning, coordination and institutional relations
3.1  Project personnel, partners and support organizations
3.2  Involved organizations, stakeholders, communities
3.3  Consultants
4) Budget
4.1  Overall yearly budget by activity
4.2  Orders of equipment and materials
B. Main text of the Yearly Plan of Activities
1  Project progress report 
This section:
i)    describes the work implemented during the elapsed Project period
ii)  describes the state of execution of the Work plan: Work plan review, progress in 
implementation of activities, inputs applied, outputs achievement
iii) presents a critical analysis of Project progress (analysis of present strengths and 
weaknesses; conclusions; justification of taken/proposed corrective action; future 
opportunities and threats)
2  Operational yearly plans 
2.1  Logical Framework Matrix (LFM)
Section 2.1. presents the LFM on one page (landscape format), and stresses in the text the 
outputs and activities differing from those in the Project document.
2.2  Outputs and activities
Section 2.2 indicates per expected output, the activities, divided into various subactivities 
as applicable, planned for the coming year.
E.g.:
Output 1.1
Activity 1.1.1
Subactivity 1.1.1.1
Subactivity 1.1.1.2
Activity 1.1.2
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Activity 1.1.3
Subactivity 1.1.3.1
Subactivity 1.1.3.2
Subactivity 1.1.3.3
Output 1.2
Activity 1.2.1
Activity 1.2.2
Activity 1.2 3
Etc.
2.3  Annual activity program
The annual activity plans should be presented in detail. The work plan in the project 
document is the basis. The activity program table (Table 2 below) should be used to present 
the activities broken down into subactivities, as applicable, which are planned for the 
coming operational year. These activities will be shown by shading the duration of their 
execution within the dark time frame which indicates the entire period of the execution 
of the activity. The table should also show the period that the activity had been executed 
in the former operational year(s), as applicable. This can be done by applying different 
shading.
Section 2.3 presents
i)  the activity program for the year under consideration, with an indication of 
responsibilities and deadlines for planned activities, conform the activity program 
table below. Where applicable each activity should be broken down into at least two 
subactivities and presented in the same table. Planned execution could be shaded in the 
black frame which indicates the implementation period of the activity and subactivity. 
With a different shading the period that the activity has been executed already in the 
former operational year(s) should also be indicated.
ii) possible indicators to follow the progress in the year this YPA is in operation. Indicators 
should somehow be related to the Output indicators in the Logical Framework Matrix 
and could be identified by questions such as: When is a specific input needed? What 
should be the progress and result of an Activity after every three months?
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Table 2: Annual activity program
Outputs/
Activities
Responsible
Party/ 
component 
task leader
Annual Activity Program (in months, second year)
10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
Output 2.1:
Activities:
Activity 2.1
Subactivities
2.1.1
2.1.2
Output 3.1
Activities
Activity 3.1
Activity 3.2
Subactivities
3.1.1
3.1.2
etc
          
Example:  Dark shading is execution in prior operational year. Light shading is planned 
activity for the coming year. The example shows that: activity 2.1 is on schedule; 
Subactivity 2.1.1 is on schedule; Subactivity 2.1.2 is expected to start one month late. 
2.4  Indicators and assumptions
Section 2.4, (only in case indicators and assumptions have to be readjusted) describes and 
justifies briefly readjustments as to indicators and assumptions.
2.5  Monitoring and reporting
Section 2.5 indicates:
i)  Implementation of the monitoring system according to the Project document or 
deviating from the planned execution.
ii) Which reports are expected to be made available to the Bio-Innovate Program during the 
coming year and what are the deadlines for handing them in?
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3 Planning, coordination and partners relations
3.1  Project team, partners and collaborating organizations
Section 3.1:
i)  Describes project team/researchers; a foreseen modification in the tasks of the Project 
team is substantiated by providing the modified activity plans.
ii)  Describes the partners in the public and private sector the Project is collaborating with 
and indicates the kind of collaboration in the coming year.
iii) Describes the organizations/institutions which are providing external support to the 
Project and the kind of support.
vi) Indicates how the Activities of component Project entities are being coordinated and 
integrated in the coming year (regular meetings, exchanges, etc.).
3.2  Involved organizations, stakeholders, communities
Section 3.2 indicates which stakeholders or interest groups are involved in the Project 
implementation, and which platforms have been established for consultation and 
dissemination in the coming year.
3.3  Consultants, if any
Section 3.3 indicates which local or external consultancy support has been foreseen during 
the coming year. The TOR is provided in the Appendix.
4 Project Budget
4.1  Overall yearly budget by activity per partner
Section 4.1 presents two kinds of budget tables:
1)  Project budget for the year under consideration by component, input and unit costs. 
This table must be produced as a consolidated budget table; and
2)  Overall Project budget by activity and component.
4.2  Orders of equipment and materials
Section 4.2 
i) describes briefly how the Project logistics are organized.
ii) indicates orders for material and equipment (local, abroad), with a transparent 
breakdown of units, unit prices, deadlines, etc.
Name: (type and sign) Position held:
Date:
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Annex 9
BIO-INNOVATE ANNUAL PROJECT TECHNICAL REPORT FORMAT 
A technical report is required for each major research topic
A. Front side of the cover page should be illustrative and present:
• Bio-Innovate logo
• Title of the Bio-Innovate consortium Project 
• Project number
• Starting date of the Project
• Title, topic of technical report
• Authors’ names
B. Back side of cover page should present:
• Consortium project PI and Co-PIs including involved technical and scientific staff that 
worked on the topic of the report
• Relevant institution’s full name, address
• The place and date the report is submitted
• Disclaimer
The following information should be provided at one of the pages following the cover page.
Table of contents
Summary
1  Introduction
2  Methodologies
3 Presentation of the data (Results)
4  Analysis and interpretation of the data and results (Discussions)
5 Conclusions
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6  Recommendations
7  Implications for practice
  Bibliography
  Appendix (es)
Summary and main text of the technical report
Summary
The summary presents the abstract(s) of the research i.e. the results and the conclusions 
reached, with an indication how the work was carried out, in such a way as to permit rapid 
reference by readers.
Main text
1  Introduction
i)  explains why the research topic is important to address, referring to the Project 
document.
ii)  presents the main theme of the work undertaken and a short reference of previous 
works in the area.
iii) indicates any specific characteristic of the Project which will not be addressed in the 
following sections.
2  Methodology
i)  presents possible options for methodologies, while referring to the Project document.
ii)  justifies and describes the materials and the methodology followed in the execution of 
the project activities
3  Presentation of the data
i)  the data collected or established by the Project as far as they are necessary for 
understanding the conclusions and/or for confirming hypothesis made or for refuting 
them. (otherwise subsidiary data and information should be included in appendix(es)).
ii)  tables, graphs and figures necessary for the explanations.
4 Analysis and interpretation of the data and results
i) explains the methods of data processing and analysis 
ii) presents the results of the analysis
iii) highlights the interpretation of the results and explains confirmation or rejection of the 
hypothesis made or expectations. If any of the results obtained is not conclusive, this 
should be stressed.
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5  Conclusions
i) the technical advancements due to the achievements of the Project
ii) its limitations 
iii) the relation between facts and theory or hypothesis.
6  Recommendations
i)  recommendations for appropriate interpretation and utilization of the Project findings.
ii)  specific recommendations for future work to be undertaken on the theme.
7  Implications for practice
Provide the practical significance of the results/ innovations emanating from the project. 
What is needed is an interpretation of the results/outputs for their implications for practice 
or impacts. This means that knowledge must be translated in conditions and practical 
measures. 
Appendix(es)
Data established by the Project, which were not presented in the main body of the Report, 
should be duly organized in tables, graphs and figures and included in the appendix(es).
Bibliography
The objective of providing bibliographic references in the report is to give readers precise 
and detailed indication of relevant written sources of information. These may include 
books, papers, leaflets, articles and magazines, among others. Although different reference 
standards exist, the following elements should be present in the Bio-Innovate project 
reports:
• the author(s)
• the title of the publication
• the edition
• place of edition
• the publisher
• the year of publication
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FORMAT FOR BIO-INNOVATE PROJECTS COMPLETION REPORT
A. Front side of the cover page should be illustrative and present:
• Bio-Innovate logo
• Title: Completion report of the Bio-Innovate Project ‘name of project’
• Project number
• Name of the implementing institution and collaborating partner institutions
B. Back side of the cover page should present:
• Starting date of the project
• Duration of the project 
• Project costs (US $)
• The original number and type of the report (e.g. Project Completion Report)
• Project technical and scientific staff - names of Project Coordinator and of project teams
• Implementing Institutions: full name, address, telephone, fax and e-mail
• The place and date the report is submitted
• Disclaimer
Table of Contents
Executive summary
1  Project Identification
1.1  Context
1.2  Origin and problem
2  Project objectives and implementation strategy
3  Project performance (Project elements planned and implemented.)
4  Project outcome, target beneficiaries involvement
Annex 10
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5  Assessment and analysis
6  Lessons learned
7  Conclusions and recommendations
Appendix 1 Project financial statement
Appendix 2 Project cash flow statements
Summary and main text of the completion report
The executive summary is meant to provide information on the main issues revealed by the 
completion report. It should be brief, no more than 2 pages. It should present very little information 
from the descriptive chapters 1 and indicate only the most relevant findings from the chapters 2, 3, 4, 
and 5. Lessons learned and recommendations could be integrally copied from the main text.
Executive summary
The executive summary:
i)  summarizes in a few sentences the Project context, origin and main problem to be 
addressed (1)
ii)  states the Project objectives and indicates the (adjusted) implementation strategy (2)
iii) presents the most critical differences between planned and realized Project 
implementation (3)
iv) provides a brief description of the situation prevailing after Project completion, as 
compared to the pre-Project situation including the situation of the target beneficiaries, 
and indicates the post-Project sustainability (4)
v)  indicates the most relevant outcome of the analysis of the Project implementation (5)
vi) communicates the lessons learned and recommendations (6 and 7)
1 Project identification
1.1 Context
Section 1.1 describes briefly:
  the social, economic and environmental context and the Project location, as well as 
relevant national and regional policies and programs (This text may comprise extracts from 
the Project document.)
1.2 Origin and problem
Section 1.2 describes briefly:
  the origin and the main problems addressed by the Project as it was originally 
conceptualized. (This text may comprise extracts from the Project document)
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2 Project objectives and implementation strategy
Section 2:
i)  states the Project rationale, the Development Objective and Specific Objectives of the 
Project as they were originally formulated in the Project document, as well as any 
adjustments made in the course of the implementation phase
ii) describes the Project implementation strategy as it was originally conceptualized (This 
text may comprise extracts from the Project document, as well as any adjustments made in the 
course of the implementation phase.)
iii) imparts identified assumptions and risks (This text may comprise extracts from the Project 
document.)
3 Project performance (Project elements planned and 
implemented)
This section merely reports on facts. Analysis and comments follow in section 5.
Section 3:
presents the Project’s achievements versus the planned performance, indicating precisely the 
differences between planned and realized Project objectives/activities.
a)  Specific Objective(s)
b)  Outputs and related Activities:
1)  as appearing in Project document
2)  added or omitted during implementation
c)  Schedule:
Starting date
Duration
d) Total amount of expenditures; analysis of applied input
4 Project outcome, target beneficiaries involvement
Here the effect of the realized activities and outputs are being described. This is the impact 
section. The recorded impact should be compared with the planned impact as described in 
the Project document.
Section 4:
i)  elaborates on the extent to which the Project Specific Objective(s) were achieved;
ii)  describes the situation existing at Project completion as compared to the pre-Project 
situation with respect to:
•  the tangible outputs of the Project
•  sectoral policies and programs
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•  the physical environment
iii) explains what participation the target beneficiaries had in the implementation of the 
Project and how its results have been used by them or will be used in the future.
iv) provides an expectation of the sustainability of the Project after its completion as a result 
of conditions prevailing at completion. Indicate any formal arrangement made with the 
Project beneficiaries for the Project’s implementation and for its continued operation or 
maintenance after completion.
5 Assessment and analysis
This section should present the main outcome of the internal evaluation which the EI together with 
stakeholders organizes shortly before Project completion. It analyzes, in retrospect and in the light of 
the actual performance (Section 3) and outcome (Section 4), the adequacy of the Project identification 
process, the quality of the Project design including the Project strategy and the planned and available 
resources and comments on the assumptions and risks. It provides the basis for the identification of the 
lessons learned which will be presented in Section 6.
Section 5:
i)  analyzes and comments on the Project rationale and the Project identification 
process emphasizing the (in)adequacy of stakeholder identification and stakeholder 
participation in the Project formulation process.
ii) analyzes and comments on the (in)adequacy of the results of the identification process 
emphasizing the correct definition of problems to be tackled, the Project Objectives, 
the choice of the implementation strategy. (Refer to Section 2.) 
iii) highlights and analysis the most critical differences between planned and actual 
Project implementation as presented in Section 3 and suggests any measures and 
actions which could have avoided these variations.
iv) evaluates and comments on the (in)adequacy of time and Project Inputs (quality and 
quantity of personnel and equipment, financial resources, knowledge and expertise) 
for Project formulation and implementation.
v)  assesses the anticipation and reality of external influences, assumptions and risks etc., 
and the effectiveness of mitigating measures.
vi) estimates, while referring to Section 4 above, the participation of anticipated and 
actual Project beneficiaries in Project implementation, how they have benefited from 
the Project (Refer also to the dissemination strategy in section 2.8 of the Project document).
vii) examines Project (in)sustainability after Project completion, referring to section  4, 
as a result of Project conceptualization, assumptions made and implementation 
conditions. (Refer also to the post-Project strategy in the Project document.)
viii) analyzes and comments on the understanding and appropriateness of the roles and 
responsibilities of the institutions involved with the Project implementation.
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6 Lessons learned
Section 5 on Assessment and analysis has provided the basis for the identification of Lessons to 
be learned for future Projects. The lessons could be classified according to the phase of the Project, 
e.g. Project identification, Project design, Project implementation, and according to the nature of 
the subjects, e.g. management and operational aspects, stakeholder participation, problem analysis, 
implementation strategy etc.
Section 6 highlights:
Lessons learned from Project identification, design and implementation as to:
a)  Project identification and design matters such as:
• aspects of Project identification and development, including problem analysis and 
stakeholder identification and participation, which most contributed to success or 
failure in achieving the Specific Objective contributing to the Development Objective.
• additional arrangements that could improve cooperation between the relevant 
Parties interested in the Project.
• aspects of Project design, including implementation strategy, which most contributed 
to success or failure in achieving the Specific Objective contributing to the 
Development Objective.
• actions to be taken to avoid variations between planned and actual implementation 
(schedule, costs, etc.); quality of Project planning.
• factors which will most likely affect Project sustainability after completion including 
dissemination strategy, post-Project strategy, and involvement stakeholders.
• other matters.
b)  operational matters such as:
• Project organization and management
• flow of funds
• definition of the roles and responsibilities of the institutions involved in the Project 
implementation
• Project documentation
• monitoring and evaluation
• external factors that influenced the Project implementation; those that could and 
those that could not have been foreseen
• other matters
7 Conclusions and recommendations
Conclusions and recommendations should preferably have a general value so Bio-Innovate partner 
countries and Executing Institutions could benefit from them. Main conclusions should be drawn 
from the combination of the above chapters. They should represent a conclusive cause-effect relation, 
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e.g. Outputs were not fully realized because required funds were underestimated. Recommendations, 
deriving from the lessons learned, should be made with a view to improve the effectiveness and 
efficiency of future similar Projects.
Section 7:
i)  sets out the conclusions and recommendations in point form, under these separate 
headings:
• Identification
• Design
• Implementation
• Organization
• Management
• etc.
ii)  comments on the potential for replication and/or for scaling up
Responsible for the Report
Name: (type and sign) Position held:
Date:
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FORMAT FOR BIO-INNOVATE PROJECTS EVALUATION REPORT 
Table of contents
Executive summary
1  Introduction
2  Evaluation scope, focus and approach
3  Project facts
4  Findings, Lessons Learned
4.1  Findings
4.2  Lessons learned
5  Conclusions and recommendations
5.1  Conclusions
5.2  Recommendations
Summary and main text of the evaluation report
Executive summary
The Executive summary is meant to provide information on the main issues revealed by the 
evaluation report. It should be brief, no more than two pages. It should present very condensed 
information from the chapters 1, 2 and 3, and indicate only the most relevant findings from the 
chapters 4.1. Section 4.2 (Lessons learned) and Section 5 (Conclusions and recommendations) could 
be integrally copied from the main text.
For thematic ex post evaluation, the first page of the executive summary should present the following 
information for each project: code number, title, Executing Institution and country in which the 
project was implemented.
Annex 11
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The executive summary describes in short:
i)  the purpose and type of the evaluation and the basic facts of the Project (Section 1 and 3)
ii)  the scope and the approach of the evaluation (Section 2)
iii) the most critical differences between planned and realized Project implementation and 
impacts, and  an analysis of causes of success or failure (Section 4.1)
iv) the financial statement
v)  and presents the lessons learned, conclusions and recommendations (Sections 4.2 and 5).
Main text
The purpose of this section is to register a description of the findings and lessons learned regarding 
the evaluated Project. It will be an important information source for guiding decisions, for future 
evaluations, as well as for building up experience from previous evaluations and for orienting new 
Projects.
The following outline is suggested:
1 Introduction
Section 1: (no more than half a page)
i)  clarifies why evaluation of the project was decided and describes the purpose of 
evaluations for the Bio-Innovate Program in general and the evaluation type, including 
any specific aspects, of this particular evaluation, e.g. thematic ex post evaluation, 
midterm evaluation.
ii)  presents project number, title and Implementing Institutions, and the Bio-Innovate 
Program Proposal context of the project (Objectives, Activities Plan and priorities it 
complies with, etc.)
2 Evaluation scope, focus and approach
Section 2:
i)  elaborates on the purpose of the evaluation, and the reason for undertaking it.
ii)  elucidates the scope and focus of the evaluation referring to the Terms of Reference for 
the evaluation mission.
iii) introduces the mission members: profession, nationality, further relevant background.
iv) sets out the approach of the task: sources of data, collection methods and measures 
adopted to ensure reliability of data collected. (e.g. documents studied, field visits, 
meetings, feedback on preliminary findings, the duration of the evaluation).
3 Project facts
The intention of this section is to summarize the most essential information and facts to understand 
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the Project intervention. The Project document contains the complete information on the Project. It 
is not useful to copy the entire information in the evaluation report.
Section 3: (length not more than half a page to one full page)
gives a brief description of the Project as a whole:
• relevant background, including origin of the project
• development objective
• main problems to addressed
• specific objective(s) and outputs
• project rationale
• starting date, duration and date of any former evaluation
• Bio-Innovate Program contribution and executing institution and collaborating agencies.
4 Findings, lessons learned
This section presents the results of the evaluation. The Terms of Reference are key to the scope of the 
evaluation and thus for the content of this section. In case of midterm and ex post evaluations, due 
consideration should be given to progress reports and the Project completion report. Particularly the 
completion report contains relevant facts and analysis, which should serve as a basis for the ex post 
evaluation, although not without critical observation. The ex post evaluation report should rather 
evaluate and summarize the findings highlighted in the completion report than repeating them all. 
The different types of evaluation will emphasize many similar objects of evaluation. Therefore it is 
possible to give a general indication of the content of this section.
4.1 Findings
In the case of ex post evaluations, include an overall assessment of its relative success or failure, and 
the extent to which failure might have been foreseen during the Project proposal appraisal process;
Section 4.1. provides a critical analysis of: 
i)  the achievements of the Project
• realized versus planned Objectives and Outputs (not applicable for ex-ante 
evaluation)
• impact and effects
• assessment of the post-project situation and of the specific conditions of 
its intended direct or indirect beneficiaries as compared to the Pre-project 
situation and expectations
• assessment of whether this post-project situation is likely to change 
additionally, in what direction and over what period
• assessment of the achievement of the Project Specific Objective(s) and of its 
contribution to the Development Objective; critical analysis of the validity of 
the Assumptions made
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• presentation of the indicators of achievement for each level of the project 
elements
• assessment of unexpected effects and impacts either harmful or beneficial
• presentation of the reasons for their occurrence
•  assessment of actual environmental impacts and comparison to the predicted 
ones
• assessment of effects, harmful or beneficial, upon local communities, related 
or not to the Project implementation
• sustainability
• assessment of the presence and effectiveness of a post-project strategy
• elaboration on the availability of human resources and financial and 
institutional provisions to guarantee sustainability
ii)  the process of Project formulation and implementation
• stakeholder involvement during the identification and during the implementation of 
the Project
•  assessment of stakeholder contribution to the design of the project
•  assessment of ownership over the project
•  assessment of (early) commitments of stakeholders and collaborating 
agencies
• appropriateness of the project design
•  its overall appropriateness
•  the rationale of its vertical logic
•  the level of detail of its work plan
•  horizontal logic, indicators, means of verification, assumptions
•  risks to Project success
• efficiency and operational aspects
• assessment of the technical, financial and managerial aspects of project 
implementation, including the adoption of norms, standards and rules 
related to technical and administrative actions, project staff coordination, 
Project organization (files, technical and financial data, reports, accounting 
documents, etc.)
• assessment of the inputs allocation, including its timing and appropriateness, 
indication of whether they are being provided on time and at the predicted 
costs; indication of probable future trends in Inputs allocation considering the 
present situation; indication of cost-effectiveness through the use of unit costs, 
comparative costs per beneficiary, etc.
• Project internal monitoring
• procurement procedures, consultants employment
• recipient country commitment
• effectiveness
• assessment of technical or scientific intrinsic merit of the project proposal
• assessment of the project proposal rationale for achieving its Objectives, 
BIO-INNOVATE   Manual  on Standard Operating Procedures
133
including a critical analysis of its Logical Framework and examination of the 
external influences which may affect the Project’s success; assessment of risks 
and success probability
• assessment of the effectiveness of the management of unexpected situations 
and evaluation of the adopted routes as compared to alternative ones
• assessment of whether the project design is still valid (for ongoing Projects) 
including the review of the Logical Framework and suggestions for its 
revision, if necessary
iii) the project proposal appraisal process
• could failures have been predicted by studying the project proposal and if so through 
what kind of indications
4.2 Lessons learned
Section 4.2 presents the corresponding lessons learned.
5 Conclusions and recommendations
In principle, conclusions may be drawn and recommendations may be made on any aspect 
highlighted in section 4. It is helpful to group conclusions and recommendations under the same 
headings as used in section 4 and with a bearing at the Terms of Reference. Recommendations 
should also refer to the conclusions they are related to. Therefore, merging sections 5.1. and 5.2 can 
be considered.  Data and information sources which support the conclusions and recommendations 
should be indicated. The use of tables for presentation of suggested revisions or for support of 
conclusions is recommended since they usually clarify proposals.
Identify any issues or problems which should be taken into account in designing similar Projects in 
future.
5.1 Conclusions
Section 5.1 presents outstanding conclusions grouped according to the headings used in 
Section 4, Findings and Lessons learned, and with a view at the TOR.
5.2 Recommendations
Section 5.2 presents recommendations grouped according to the headings used in section 4 
and target groups e.g. executing institution, collaborating Institutions, Bio-Innovate 
Program secretariat, TAC expert panel, etc.
Appendix: Executing institution’s/consortium project leader’s views
The appendix presents any views of the EA which deviate from the conclusions of the 
evaluation team.
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Annex 12
CHECKLIST FOR BIO-INNOVATE PROJECT EVALUATION MISSION 
This checklist contains issues for checking which may help evaluation mission members in 
carrying out their evaluation. Evaluators do not necessarily need to address all the issues.
• Is there a clear understanding of the field or subsector involved and of its main 
characteristics?
• Does the problem analysis confirm the results of the project identification?
• Are there better technical, financial, or administrative approaches for the Project?
• Does the analysis of the Logical Framework linkages lead to the conclusion that the 
Project rationale is appropriate?
• Are the Outputs necessary and sufficient to achieve the Specific Objective(s)?
• Are the Activities and related Inputs necessary and sufficient to achieve the Outputs?
• Is the project budget appropriate for the project intent? Are the costs of each input 
appropriate?
• Will the project be cost-effective overall?
• Does the level of detail of the Activities allow appropriate definition of related Inputs 
and costs?
• Will the results of the project be sustainable, financially and in other ways?
Additional issues specifically for midterm evaluations:
• Have external events so far conformed to the expectations of the project? In particular 
do the assumptions still appear valid? If not, why not?
• Has progress so far matched the implementation plan? If not, can action be taken to 
restore or improve the original project track? If not, what should be done?
• Is the Project still valid in terms of its Specific Objective(s) and planned Outputs? Is 
there any need for changes or adjustments?
• Is the project budget and its original cost-effectiveness still valid?
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• Are the expected impacts materializing? If not, what should be done?
Additional issues specifically for ex post evaluations:
• What happened to the project, and what problems arose?
• Were the Inputs provided as planned and were work schedules observed?
• Were the expected Outputs achieved?
• What problems (if any) caused delays and what consequences did this have on 
implementation?
• Was the management and execution of the project adequate?
• How did actual costs compare with budget provision?
• Were the Specific Objectives relevant? Did the project achieve its Specific Objective(s)?
• Did these Objectives change during implementation?
• Were there unexpected results and impacts, either harmful or beneficial? Who in fact 
benefited from the Project?
• Could the Specific Objective(s) have been achieved more efficiently through an 
alternative design?
• What are the key lessons from the project? Which good or bad factors contributed to its 
relative success or failure?
• Does the project show up new problems which need to be examined in designing future 
interventions?
• What direct recommendations arise either for future similar projects or for the continued 
operation of this one?
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